GENEREX: EIN MILLIARDENMARKT!!!! - 500 Beiträge pro Seite

[therman]

Hi,

Behandlung von Diabetes ist ein Milliardenmarkt, und wird
noch weiter wachsen.
Generex Biot. entwickelt eine Verabreichungtechnologie
für Insulin. Es ist ein Mundspray, es wird schnell
aufgenommen und kann genau dosiert werden.
Die Entwicklung ist im Enstadium.

Diese Drug-Delivery-Technologie wird auch noch für weitere
Medikamente brauchbar sein und entwickelt.

Meiner Meinung nach sehr interessant
http://www.generex.com/


Oralin is our pioneering contribution to diabetes management. It`s a unique oral insulin formulation that is delivered directly into the mouth via our RapidMist device, where it`s rapidly absorbed into the bloodstream through the buccal mucosa.

At Generex, we`re turning possibility into reality. Our proprietary platform technology creates an outstanding opportunity to develop a product pipeline that potentially can carry a large number of specific applications, each with remarkable promise.

Now that we`re in the final stages of developing our oral insulin formulation, we`re looking ahead to the next applications of our platform technology. We`ve begun research on four specific target molecules: morphine, fentanyl, heparin, and flu vaccine.

Morphine is a narcotic alkaloid of opium, used medically for pain relief and as a sedative.

Fentanyl is a synthetic opioid analgesic, used medically for pain relief and as a sedative. It is more powerful than morphine, and has a rapid onset of action and a relatively short duration of action.

Heparin is a glycosaminoglycan, used medically as an anticoagulant (blood thinner).

Flu vaccine contains inactive influenza viruses (usually three), and is used to protect against or minimize the symptoms of particular strains of influenza. Flu vaccines are altered yearly according to predictions of which flu strains will be most prevalent.

We`re looking forward to the challenge of perfecting the pain-free delivery of these and other target large molecules.

Generex. Pursuing innovation, improving quality of life.

[amorphis]

@therman...Drug-Delivery-Technologie wird auch von der deutschen nbx entwickelt!kennst du dich auch mit diesem wert aus?wenn...sind die beiden technologien miteinander vergleichbar?

gruß

[therman]

Hi amorphis,

Mit nbx, November http://www.november.de/index.php
habe ich bisher mich noch nicht beschäftigt.

War gerade auf deren Homepage, konnte jedoch nichts
über Drug-Delivery-Technologie finden.

Zu GENEREX:
Die Marktkapitalisierung beträgt zur Zeit ca. 45Mio. §.

Wenn das Insulinspray die Zulassung erhält, meiner Meinung
nach sehr wahrscheinlich und nur eine Frage der Zeit,
dann dürfte sich der Aktienkurs mehr als verzehnfachen.

Solange jedoch noch kein Produkt auf dem Markt ist, wird
die Aktie ein Spielball der Spekulanten und Zocker sein.
Doch das wird sich ändern.
Kaufen und liegenlassen ist hier meine Devise.
Und ab und zu dazukaufen.

therman

[amorphis]

sorry...da ich mich viel mit nbx beschäftige habe ich dieses wissen vorausgesetzt!du mußt bei der ausgegliederten responsif gmbh gucken!nbx besitzt eine option wieder eine beteiligung an responsif einzugehen (bis zu 50%) und im falle eines positiven geschäftsverlauf teilzuhaben!

http://www.responsif.de/therapeutics/vlp_d.htm

[amorphis]

die kaufen und liegen lassen strategie zieht auch bei nbx!setz dich mal mit dem wert auseinander...oder besuch mal nbx thread von odppa!dieser ist ziemlich informativ und hier versammeln sich alle nbx experten...

zumal nbx in kürze wirklich vor mehreren produkteinführungen steht...gruß amorphis

[therman]

Hi amorphis,

war auf der Homepage von responsif.
Habe festgestellt, dass dieses Jahr die ersten klinischen
Versuchsreihen Phase I begonnen wurden.

Bis zum fertigen Produkt dürften also ca. noch 5-6 Jahre
vergehen.
Sobald erfolgreiche Ergebnisse bekannt werden, wird
November in dieser Hinsicht sicherlich sehr interessant
werden.

therman

[amorphis]

responsif ist wie gesagt nur ein standbein von vielen...die haben noch weitaus dickere pferde im stall!

[therman]

Hi amorphis,
ich werde mir den Thread zu nbx mal anschauen, Du hast
mich neugierig gemacht.

Zu Generex:

Pharmabrand ist Vertriebspartner in Mittel- und Südamerika,
wo es ca. 11 Millionen Diabeteskranke gibt.


Generex Exhibits at 12th Latin American Diabetes Congress
Tuesday October 5, 8:01 am ET
Company positioning Oralin(TM) as an interventional agent for the control of postprandial glucose and as a preventative agent in respect of (i) the onset of diabetes in patients with impaired glucose tolerance, and (ii) prevention of complications in patients with type 2 diabetes


TORONTO, Ontario, Oct. 5 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News) announced today that Oralin(TM), the Company`s proprietary oral insulin spray formulation, and its RapidMist(TM) Diabetes Management System were featured by PharmaBrand S.A. at its exhibit at the Latin American Diabetes Association 12th Latin American Diabetes Congress held in Sao Paolo, Brazil, September 26 - 29, 2004. PharmaBrand, a pharmaceuticals company based in Quito, Ecuador, is the Company`s joint venture partner for the commercialization of Oralin(TM) in Central and South America. Attendee interest in Oralin(TM) was high, with more than 2,500 pieces of information on Oralin(TM) being distributed from the exhibit.
"This congress represents a successful introduction of the concept of Oralin(TM) as a diabetes treatment in Central and Latin America and we are pleased by the enthusiastic reception of the healthcare professionals attending the congress ," said Dr. Roberto Cid, President of PharmaBrand. "We look forward to the prosecution of the Oralin(TM) dossier for marketing and distribution submitted to the Ecuadorian Ministry of Public Health in August."

The International Diabetes Federal (IDF) estimates that there are approximately 11 million adults with diabetes in Central and South America, representing a prevalence of 4.8%.

Diabetes Action Now is a joint program of the World Health Organization and the IDF. In a Diabetes Action Now podium presentation at the congress, diabetes was described as an "international epidemic" requiring long-term management of risks and co-morbidities across the boundaries of many specialties such as nephrology, neurology, cardiology, perinatology, and surgery. A partnership has been proposed between Diabetes Action Now and the International Diabetes Center (IDC) which will focus on prevention, early detection and intensive treatment to prevent complications associated with diabetes.

Oralin(TM) is a liquid formulation of regular human insulin that is delivered to the buccal mucosa by way of the RapidMist(TM) device, a device similar to an asthma device, however, absorption is limited to the buccal mucosa with no entry into the lungs. The rich vascularity of the buccal mucosa allows for much faster absorption of insulin and a shorter total duration of activity which makes Oralin(TM) an ideal prandial insulin as it can be conveniently administered immediately prior to meals with little prospect of hypoglycemia.

In an IDC podium presentation at the congress entitled "Diabetes and Obesity in America", it was noted that approximately 20 million Americans suffer from pre-diabetes. People who have blood glucose levels that are higher than normal but not high enough to be type 2 diabetes have pre-diabetes, also know as "impaired glucose tolerance" (IGT). In individuals with IGT, the body does not use insulin efficiently, forcing the pancreas to work harder to reduce blood glucose levels. Eventually, the pancreas tires and type 2 diabetes begins. In addition, conventional oral medications currently used to treat patients with type 2 diabetes accelerate the degradation of pancreatic function and the consequent insulin dependence, resulting in insulin requiring type 2 diabetes.

Generex believes that Oralin(TM) can be used as a preventative pharmacologic agent by people with pre-diabetes to delay the onset of diabetes and by patients with type 2 diabetes to delay the onset of insulin dependence and the complications associated with diabetes that can affect the eyes, heart, kidneys, feet and sexual function, primarily due to blood vessel damage.
Data from the 10-year Diabetes Control and Complications Trial concluded in 1993 and the United Kingdom Prospective Diabetes Study that ended in 1999 showed that keeping A1C in target helps to prevent or slow the progress of diabetes complications. Just a 1% drop in A1C can decrease the risk of eye, kidney and nerve damage by 25 - 30%.

[therman]

News

Generex Biotechnology Executive Presents at 4th Annual Biotech in Europe Investor Forum
Wednesday October 6, 8:31 am ET


TORONTO, Oct. 6 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News) announced today that Dr. Gerald Bernstein, the Company`s Vice-President for Medical Affairs, made a presentation at the 4th Annual Biotech in Europe Investor Forum on October 5, 2004 in Zurich, Switzerland. The presentation was a description of Oralin(TM), the Company`s proprietary oral insulin spray formulation, and the RapidMist(TM) Diabetes Management System.

The forum is a high-profile event organized by Sachs Associates in association with Bloomberg L.P. and attended by an executive-level audience of over 450 investors, pharmas, fund managers and capital-raising companies.

[therman]

GNBT hat noch andere "Eisen" im Feuer.

z.B.
Vaccine zur Krebsbehandlung, Brustkrebs.

Generex Biotechnology Establishes CRADA with the Uniformed Services University and the Henry M. Jackson Foundation for Novel Her-2/neu Vaccine Studies and Clinical Trials at Walter Reed Army Medical Center in Patients with Breast Cancer
Tuesday September 28, 8:05 am ET
Company Collaborates with Leading Translational Investigator Experienced in Peptide Vaccine Trials


TORONTO, Sept. 28 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News) announced today that its wholly owned subsidiary, Antigen Express, has entered into a Collaborative Research and Development Agreement (CRADA) with the Uniformed Services University of the Health Sciences (USU) and The Henry M Jackson Foundation for the Advancement of Military Medicine, Inc. (Foundation) to work with LTC George Peoples, MD, Medical Corps, U.S. Army, to advance HER-2/neu vaccine efforts for breast cancer. Dr. Peoples is assigned to the Walter Reed Army Medical Center (WRAMC) and works in conjunction with the Clinical Breast Care Project (CBCP). The CBCP is a Congressionally mandated civilian-military collaboration between WRAMC, USU, the Windber Research Institute (Windber, PA) and the Foundation. The mission of the CBCP is to undertake advanced research in breast cancer prevention, diagnosis, and treatment. HER-2/neu vaccine efforts under the CRADA will incorporate the Antigen Express proprietary Ii-Key technology to stimulate cancer patients` immune cells to attack HER-2/neu expressing tumor cells. Prior studies have shown this technology to be successful in stimulating cancer patients` immune cells in test tubes and in live animal models.
ADVERTISEMENT


"Collaboration with Dr. Peoples and the CBCP will significantly strengthen our HER-2/neu vaccine development efforts and our ability to perform expeditious and meaningful clinical trials," said Eric von Hofe, Vice President for Technology Development at Antigen Express. Dr. Peoples has already conducted several clinical trials with unmodified HER-2/neu peptides. The results of those studies showed some immune stimulation and possible benefits to patient outcome. "The added stimulation provided by Antigen Express peptide modifications has a good chance of increasing response sufficiently to result in clear-cut efficacy," said Dr. von Hofe.

Antigen Express technology focuses on antigen-specific augmentation of the T helper component of the immune response. While early peptide vaccines focused on stimulating cytotoxic T cells (CTL), the importance of the T helper response is now viewed as crucial to mounting an effective anti-tumor response. "The clinical importance of T helper stimulation has been shown most clearly by adoptive transfer trials conducted at the National Institutes of Health," explained Dr. Robert Humphreys, Chief Scientific Officer at Antigen Express. "Without T helper cells there was essentially no response to the therapy, while the addition of T helper cells back to the mix of stimulated lymphocytes re-infused into the patient resulted in nearly a 50% response rate," continued Dr. Humphreys.

The strategy employed by Antigen Express is to develop a peptide vaccine that forces antigen specific stimulation of T helper cells. This vaccine strategy is dramatically simpler and less expensive than adoptive transfer. The core of the technology is modifying antigenic peptide epitopes (e.g., from the HER-2/neu cancer-related antigen) that force them to be presented to T helper cells by MHC class II molecules, which are the immune system`s gatekeeper for antigen-specific T helper stimulation. Additional applications using this technology to target other cancers, viral infections and autoimmunity are in development.

[therman]

GNBX

ich denke, der jetzige Kurs ist eine Gelegenheit zum
Einstieg.

ich selbst bin gestern zu 1,04 eingestiegen und habe heute
bei 1,02 aufgestockt.
Es ist natürlich ein Risiko da, dass es kurzfristig noch tiefer geht, aber das wäre eine sehr gute Nachkaufgelegenheit, denke ich.

Langfristig bietet sich hier eine Chance auf
aussergewöhnliche Kursgewinne.

therman

[therman]

Hi,

GNBT ist genau wie INSM ein Kandidat für aussergewöhnliche
Kurssteigerungen.
habe nochmals bei 0,91$ nachgelegt.

NEWS:

Generex Exhibits at 12th Latin American Diabetes Congress
Tuesday October 5, 8:01 am ET
Company positioning Oralin(TM) as an interventional agent for the control of postprandial glucose and as a preventative agent in respect of (i) the onset of diabetes in patients with impaired glucose tolerance, and (ii) prevention of complications in patients with type 2 diabetes


TORONTO, Ontario, Oct. 5 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News) announced today that Oralin(TM), the Company`s proprietary oral insulin spray formulation, and its RapidMist(TM) Diabetes Management System were featured by PharmaBrand S.A. at its exhibit at the Latin American Diabetes Association 12th Latin American Diabetes Congress held in Sao Paolo, Brazil, September 26 - 29, 2004. PharmaBrand, a pharmaceuticals company based in Quito, Ecuador, is the Company`s joint venture partner for the commercialization of Oralin(TM) in Central and South America. Attendee interest in Oralin(TM) was high, with more than 2,500 pieces of information on Oralin(TM) being distributed from the exhibit.

Weiter NEWS:

Generex Biotechnology Presents Information at the Euroconference Vaccines 3 Meeting of the Pasteur Institute in Paris on the Use of Novel Peptide Vaccine for Melanoma
Tuesday October 12, 8:31 am ET
Transgenic Mice Studies with Genes for Human HLA-DR Support Potential Use of T-Helper Cell Peptide Vaccine for Cancers


TORONTO, Oct. 12 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News) announced today that Dr. Robert Humphreys, founder of its Antigen Express immunomedicines subsidiary, delivered a presentation on October 7 at the Euroconference Vaccines 3 meeting of the Pasteur Institute in Paris, France.
ADVERTISEMENT


Dr. Humphreys presented: "Enhanced T Helper Cell Epitope Peptide Vaccines for Melanoma." This presentation summarized work on a novel concept in melanoma vaccination by Antigen Express scientists during the past year in a special mouse model for melanoma vaccines. The transgenic mice used in this model contain the human HLA-DR molecules which present the vaccine peptides to mouse T helper cells. This is an advanced preclinical model, offering support for an Investigational New Drug filing for clinical trials.

Cancer clinicians in many academic cancer centers state that peptide vaccines have potential for immunotherapies of established and potentially recurrent cancers. Melanoma is one of the most advanced models for identification and use of such peptide vaccines.

Many vaccine peptides have been developed for stimulation of patients` cytotoxic T lymphocytes to kill cancer cells. However, clinical trials with such vaccine peptides do not have particularly robust results. The reason for this lack of potency stems in part from the fact that those vaccine peptides do not boost T helper cells, which upregulate the cytotoxic T lymphocytes and provide long term immunological memory.

Specific T-helper cell vaccine peptides that have been investigated are not potent because such peptides bind only weakly to the specialized receptors, which present the peptides to T-helper cells. Antigen Express` scientists have discovered and patented a method to enhance such presentation of peptides to T-helper cells.

The mechanism has been to create a hybrid linking the peptide recognized by T-helper cells through a simple chemical linker to an immunoregulatory segment of the Ii-protein (the Ii-Key peptide). Such Ii-Key peptide linked - epitope peptide hybrids are presented 200 times more effectively than the epitope-only peptide in vitro. Mice immunized with Ii-Key/antigenic epitope HIV hybrids demonstrated a 4-6 fold greater enhancement of Th1 cells than did mice immunized with HIV epitope-only peptides as measured by an immunological assay specific for T-helper cells.

Applying these methods to melanoma, Antigen Express scientists found similar results with Ii-Key hybrids containing melanoma epitopes. The enhancement of T helper activation probably augments cytotoxic T lymphocyte activity by stimulating dendritic cells. Thus, Ii-Key/melanoma hybrids for T helper cells can be used in combination with cytotoxic T lymphocyte epitope peptides for maximal clinical therapeutic effect.

The potency of other kinds of vaccine peptides is also greatly increased when linked to the Ii-Key active molecule. In addition to melanoma, Antigen is pursuing programs for the use of such vaccines for breast, colon and ovarian carcinomas as well as for HIV, SARS, and smallpox. Hybrids of the Ii- Key linked chemically to a number of antigenic epitopes have been demonstrated to be potent vaccines in mouse models.

Antigen Express has received 9 grants from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the Department of Defense for the development of these compounds for many vaccine and treatment purposes.

[therman]

heute nochmal nachgekauft zu 0,79$.

News:

http://biz.yahoo.com/prnews/041101/nym116_1.html

Generex Biotechnology Reports Details of Studies Presented at Two Professional Conferences
Monday November 1, 9:21 am ET


TORONTO, Nov. 1 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News), a leader in the area of buccal drug delivery, today reported the details of data from studies sponsored by the Company and presented last week at the 8th Annual Canadian Diabetes Association / Canadian Society for Endocrinology and Metabolism Professional Conference and Annual Meetings in Quebec City, Quebec, Canada and the Fourth Annual Meeting of the Diabetes Technology Society in Philadelphia. The studies address the efficacy of the Company`s proprietary Oral-lyn(TM) oral insulin spray formulation and RapidMist(TM) Diabetes Management System.
Gerald Bernstein, MD, FACP, past president of the American Diabetes Association and Vice President for Medical Affairs at Generex Biotechnology commented, "the highly significant data presented below places Ora-lyn in its unique position as a pivotal therapeutic in the management of diabetes mellitus. The data show that Ora-lyn action is dose related and highly reproducible in the same individual. Glucose clamp studies show that Ora-lyn is distinct in its rapid onset of action but equally important is the observation that Ora-lyn action ends at 120 minutes. There appears to be no tail of insulin action virtually eliminating hypoglycemia when used as a prandial insulin. Finally, a 12 week long term study shows that Ora-lyn added to glargine and metformin lowers A1c hemoglobin by 0.84. In addition to Ora-lyn, Generex is developing additional products to create a full panel to treat multiple aspects of diabetes."

Dr. Bernstein concluded "Generex is positioning itself as a broadbased diabetes and cardiovascular disease company by developing a pipeline of products that are preventative as well as interventional. Along with Ora-lyn, there will be supporting products to improve quality of life and ease the burden of diabetes for millions.

therman

[therman]

Hi,

weiterhin gute News bei GNBT.

noch kann man günstig einsteigen.

Ich erwarte mittel bis langfristig mindestens eine
verzehnfachung des Kurses.

Generex Biotechnology Introduces Glucose Spray; First Product of the Diabetes Management System to Reach the Market
Company enters into Marketing Agreement with PharmaBrand to soon launch GlucoSpray
11/3/2004 9:19:00 AM
TORONTO, Nov 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- Generex Biotechnology Corporation (GNBT), a leader in the area of buccal drug delivery, announced today that it is actively engaged in the research and development of GlucoSpray(TM), a proprietary oral glucose spray formulation, to be delivered by way of the Company`s proprietary RapidMist(TM) device.

Generex`s preliminary research and development efforts have demonstrated that glucose in the Company`s proprietary formulation (GlucoSpray(TM)), can be delivered into the body very rapidly through the buccal mucosa in the mouth using the Company`s proprietary RapidMist(TM) device, with glucose appearing in the blood within five minutes. As a result, precious minutes of relief should be provided to the brain thereby preventing some comas and ameliorating symptoms earlier. GlucoSpray(TM) could be conceivably administered to a comatose patient.

Generex also announced today that it has entered into an agreement with PharmaBrand S.A., a leading distributor of pharmaceutical products in Central & Latin America, for the marketing and distribution of GlucoSpray(TM) in Ecuador following receipt of speedy governmental approvals. Following test marketing in Ecuador, the arrangement may be expanded to other Central & Latin American countries.

[Kox]

Seit gestern bin ich in Generex investiert.
Und was mußte ich heute lesen?
Pfizer entwickelt zusammen mit Sanofi-Aventis ein inhalierbares Insulin, was Mitte nächsten Jahres ein Zulassungsantrag erhalten soll.
Ich bin auch in Pfizer investiert und überlege meine Investition in Gererex aufzugeben.
Was spricht denn noch für Generex?
Droht vielleicht Patentstreit?

Mit freundlichen Grüßen

Kox

[tasmandevil]

Keine Ahnung warum der Wert derartig durchsackt.
Kann keine "Bad News" finden.
Bin noch drin und bleibe drin.

Generex Biotechnology Corporation (GNBT) Announces Publication Of Oral-lyn(TM) Research Study
TORONTO, Nov. 30 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NasdaqSC: GNBT), a leader in the area of buccal drug delivery, today announced that well-known diabetes investigator Dr. Jaime Guevara- Aguirre of the Institute of Endocrinology, Metabolism and Reproduction in Quito, Ecuador has published an Oral-lyn(TM) research paper in the November/December 2004 edition (Volume 20, Issue 6) of Diabetes/Metabolism Research and Reviews (Copyright (C) 2004 John Wiley & Sons, Ltd.).

INVESTMENT HIGHLIGHTS
Investment Highlights

1. Market Opportunity: Market size for injectable drugs in a non-injectable form is estimated to be $15 billion.
2. Proven Technology Platform: RapidMistTM allows for the buccal delivery of drugs, thereby replacing needle injections.
3. Broad Product Pipeline: Oral Insulin (Diabetes), Morphine & Fentanyl (Pain Management), Low Molecular Weight Heparin
(Cardiovascular), and Oral vaccines and diagnostic kits (HIV / AIDS, SARS).
4. ORALIN - Oral Insulin Spray: Phase IIB Clinical studies ongoing. Has shown similar results as compared to injection.
5. Antigen Express, Inc. – Generex subsidiary, focused on the development of immunomedicines. Received grants totaling
$1.85 million. Six issued patents. Two platform technologies: Ii-Key hybrid peptides & Ii-Suppression.
6. Strong Financial Position: Currently with ~ $8 Million in Cash & Short-Term Investments.
7. Experienced Management Team: Averaging over 100 years of industry experience.
8. Strong Patent Position: 18 patents and applications covering large molecule drug delivery; 4 patents and applications
pertaining to other drug delivery technologies.

RECENT CORORATE HIGHLIGHTS
Recent corporate Highlights

31-Aug-2004 Generex Submits Oralin(TM) Dossier to the Ecuador Ministry of Public Health
26-Aug-2004 Generex Expands Joint Venture With PharmaBrand
25-Aug-2004 Generex Receives $1 Million Non-Refundable Deposit Under Letter of Intent with Sejong
18-Aug-2004 Generex Expands HIV Vaccine Efforts With Leading MGH Investigator

> www.generex.com

tasmandevil

[therman]

Hi,

hab gestern nochmals zu0,70$ gekauft.

Ein drohendes Delisting von der Nasdaq hatte den Kurs in letzter Zeit gedrückt.
Heute die erlösende Nachricht: Das drohende Delisting ist abgewendet:

Jetzt kann es wieder aufwärts gehen.

Hier die Nachricht.

Generex Biotechnology and Elan Agree to Terminate Dormant Joint Venture
Tuesday December 21, 8:30 am ET
Generex Shareholders` Equity to Increase Through Conversion of Preferred Stock
Transaction Will Allow Company to Meet Nasdaq Minimum Stockholders` Equity Requirements


TORONTO, Dec. 21 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News) announced today that it has entered into an agreement which will result in the conversion of $14.3 million of Generex preferred stock owned by Elan Corporation PLC into Generex common stock at the voluntary conversion ratio of $25.277 per share specified in the original terms of the preferred stock. Shares of Generex closed Monday at $0.65.
ADVERTISEMENT


When this transaction is completed, the full value of the outstanding preferred stock will be added back to Generex stockholders` equity in its financial statements for the current quarter, increasing the Company`s net worth by $14.3 million. This will result in stockholders` equity exceeding the minimum stockholders` equity requirements of Nasdaq Marketplace Rule 4310(c)(2)(B).

The transaction will also resolve all other aspects of the Company`s relationship with Elan. In connection with the establishment of a joint venture in 2001, Generex issued certain preferred shares to Elan which had originally been classified as equity. Subsequently, in connection with the audit of Generex`s financial statements for the fiscal year ended July 31, 2002, those preferred shares were removed from the Company`s stockholders` equity and re-classified as mezzanine equity. This resulted in a reduction of Generex`s stockholders` equity by the value of the outstanding preferred stock, at that time approximately $12 million.

Pursuant to an arrangement between Generex and Elan, Elan has agreed to sell the preferred stock to a third party on terms which will require the third party to immediately on closing convert all of the outstanding preferred stock into Generex common stock at the preferred stock conversion ratio of $25.277 per share for an aggregate of 534,085 shares. The closing could take place as early as December 22, 2004.

Generex and Elan have agreed to terminate the joint venture and mutual releases will be exchanged. The parties had agreed to pursue the development of buccal morphine technology through the joint venture. Generex will now be free to pursue buccal morphine on its own or with a new partner.

[tasmandevil]

Hab auch nochmal ein paar k nachgelegt.
Denke auch das dies der Boden gewesen sein dürfte.
Bei Zulassung von Oralin sollten kurzfristig 3$ drin sein.


tasmandevil

[asics01]

hallo therman
nach genauerem studieren deiner generex bin ich heute auch mal eingestiegen.jetzt warte ich nur noch mal auf eine günstige gelegenheit um bei antigenics noch mal reinzukommen.

gruß asics

[therman]

Hallo asics,

bei AGEN warte ich ebenfalls noch ab.
Denke die Korrektur kann bis ca. 7$ gehen.
Noch sehe ich jedenfalls kein Ende der Konsolidierung
bei AGEN.

Ich rechne bei GNBT mit einem kräftigen Kursanstieg.
Angesichts des riesigen Marktes für Diabetes ist die
Marktkapitalisierung von GNBT mit zur Zeit 24 Millionen
sehr moderat.
Es gibt selbstveständlich andere Wettbewerber mit Insulin-verabreichung
ohne Spritze. Aber ich denke GNBT hat gute Chancen ein großes
Stück von dem "Kuchen" zu bekommen.

therman

[asics01]

tja die konkurenz ist sehr groß und schläft nicht,ich sehe das als zock.ich denke nach der korrektur haben die noch ein paar prozent gut.sag wieviel hast du denn im depot wenn du immer nachgekauft hast ??

auf gutes gelingen

[therman]

Hallo asics,

ich habe jetzt 10.000 GNBT im Depot mit DurchschinttEK 0,805.

Ich denke aus GNBT kann mehr als nur ein kurzer Zock werden.

Wenn die mit ihrem Insulinspray erfolgreich sind halte ich eine

Verzehnfachung oder sogar mehr in den nächsten Jahren für
durchaus möglich.

gruss therman

[therman]

Hi,

gestern habe ich eine Anfrage an den Präsidenten von Generex gerichtet,
bezüglich des Produktes Oral-lyn, das Insulin-Spray.
Schon heute erhielt ich diese erfreuliche Antwort:


Mr. S....,

It is always a pleasure to hear from a shareholder. As you are aware, we are presently conducting long term Phase II b studies of Oral-lyn on Type 1 and Type 2 diabetes patients. Simultaneously, the company anticipates that it will receive registration of Oral-lyn in Ecuador in the first quarter of 2005. This registration will allow the company to market Oral-lyn in Ecuador and the rest of the Andean Pact countries including Venezuela and Colombia. This region will be a test market for Oral-lyn.

We are in discussions with a number of big pharma companies and we hope that we will enter the South American market in 2005 with a partner as a co-marketer. We will continue to negotiate with pharma until we reach a global development/marketing plan for Oral-lyn.

We thank you for your continuing support and we will be pleased to keep you posted with our progress.

Regards, Generex Biotechnology

Thank you,
Rose C. Perri
CFO, COO, Treasurer, Sec., Director


therman

[therman]

GNTB

durchbricht heute den Widerstand bei 0,80

Intraday jetzt bei 0,85, 12% plus.

Nächstes ziel 1,00$

therman

[therman]

Generex Achieves Compliance with Nasdaq Market Place Rule 4310(c)(2)(B)
Tuesday January 4, 8:30 am ET
Generex and Elan Terminate Dormant Joint Venture


TORONTO, Jan. 4 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NasdaqSC: GNBT) announced today that it has completed its previously announced agreement with Elan Corporation PLC which has resulted in the conversion of $14.3 million of Generex preferred stock, previously issued to Elan in connection with a joint venture for the development of buccal morphine technology, into Generex common stock at the voluntary conversion ratio of $25.277 per share specified in the original terms of the preferred stock. In connection with the transaction, Elan sold the preferred stock to a third party purchaser who immediately converted the preferred shares into common stock for an aggregate of 534,085 common shares.
ADVERTISEMENT


As a result of the transaction, Generex`s stockholders` equity has increased by $14.3 million. On a pro forma basis as at the quarter ended October 31, 2004, the transaction would have resulted in stockholders` equity of $9,522,000, significantly in excess of the NASDAQ minimum stockholders` equity requirement. Generex continues to satisfy the minimum stockholders` equity requirement of Market Place Rule 4310(c)(2)(B) as at the date hereof and understands that it is not currently the subject of any de-listing proceedings based on non-compliance with the Rule.

The transaction has also resolved all other aspects of the Company`s relationship with Elan. The joint venture has been terminated and the parties have retained sole ownership of their respective intellectual properties. Generex intends to pursue the development and commercialization of buccal morphine.

[therman]

GNBT

legt heute weitere 5,88% zu.

http://www.wallstreet-online.de/si/charts/charttool.php?edit…

[therman]

Hi,

jetzt erfolgt ein Pullback auf den überwundenen Widerstand
bei 0,80 $.
Gelegenheit zum nachlegen.

Verläuft dieser erfolgreich befindet sich der nächste Widerstand bei 1$.

therman

[therman]

Generex Biotechnology Announces Publication of Oral-lyn(TM) Research Study
Wednesday January 12, 1:00 pm ET


TORONTO, Jan. 12 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NasdaqSC: GNBT), a leader in the area of buccal drug delivery, today announced that well-known diabetes investigators Dr. Itamar Raz, Dr. Simona Cernea, Dr. Miriam Kidron and Dr. Jay Wohlgelernter, all of the Diabetes Unit, Department of Internal Medicine, Hadassah-Hebrew University Hospital, Jerusalem, Israel, together with Generex consultant Dr. Pankaj Modi, have published an Oral-lyn(TM) research paper in the December 2004 edition (Volume 26, Number 12) of Clinical Therapeutics®, an international peer- reviewed journal of drug therapy (Copyright © 2004 Excerpta Medica, Inc.).

The paper is entitled Comparison of Pharmacokinetic and Pharmacodynamic Properties of Single-Dose Oral Insulin Spray and Subcutaneous Insulin Injection in Healthy Subjects Using the Euglycemic Clamp Technique. In this study in a small, selected population of healthy male subjects under euglycemic conditions, Oral-lyn(TM) was associated with a higher Cmax, shorter Tmax, and faster time to peak glucose uptake compared with subcutaneous insulin. The short Tmax and the 120-minute duration of effect of Oral-lyn(TM) suggest that it may be a promising alternative for fulfilling meal-related insulin requirements in persons with diabetes.

Clinical Therapeutics®, published monthly, provides peer-reviewed publication of original reports of recent developments in drug therapy as well as in-depth review articles on specific drug therapies or disease states. The journal serves an international audience of scientists and clinicians in a variety of research, academic and clinical practice settings by quickly disseminating research findings. All manuscripts are peer reviewed for clinical relevance, technical accuracy, methodologic rigor, clarity and objectivity by independent specialists.

[therman]

Hi,

bei GNBT scheint sich eine Untertassenformation zu entwickeln
mit Ziel ca. 1,2$ in den nächsten Wochen.

Die Unterstützung bei ca. 0,80$ sollte dabei halten.

therman

[therman]

Hi,

hier der Chart:

http://www.wallstreet-online.de/si/charts/charttool.php?edit…

therman

[therman]

Hi,

ich hatte gestern ein Gespräch mit Anna E. Gluskin, CEO von GNBT.

Was wir dieses Jahr erwarten können ist:

1. Zulassung von Oral-lyn in Lateinamerika im 1.Quartal.
2. Beginn der Vermarktung in Lateinamerika im Laufe des Jahres 2005.
3. Beginn der Phase III Studien für eine Zulassung in USA.
4. Gespräche für eine Zulassung in Deutschland u. Europa sind im Gange.
5. Gespräche mit einem Major Partner zur Vermarktung sind im Gange, u. a. auch mit Merck.

Merck wäre ein geeigneter Partner, denn sie haben noch kein
Produkt zur alternativen Insulinversorgung in ihrem Programm.

6. Gespräche mit weiteren Partnern zur globalen Vermarktung
von Oral-lyn sind im Gange.

Ob alle Punkte erwartungsgemäß ablaufen, bleibt natürlich abzuwarten.

therman

[therman]

HI,

habe nochmal nachgekauft.


News:Techrumormill is featuring Generex

Insulin Inhalers will be a multi Billion US Dollar industry
Rumored By: Biotechguru
Date: January 21, 2005 06:45PM

Insulin Inhalers will be a multi Billion US Dollar industry

For the first time since insulin injections were introduced 75 years ago, non-invasive insulin therapy may finally be on the horizon. Thanks to a new insulin inhaler developed and manufactured by Generex, researchers say, the daily injections many diabetics take may become relics of the past. Over 20 million Americans and Canadians suffer from diabetes. One of every 10 of those inject insulin to control their blood sugar, sometimes requiring multiple painful injections each day.

The new inhaler by Generex will make their lives much easier, once approved by the FDA. The inhaler sprays insulin out into the mouth like a mist, which coats the membranes of the mouth, throat and tongue. The insulin then passes quickly through the oral tissue into the bloodstream. Doctors say, patients overwhelmingly prefer this new device over insulin shots. They hope the inhaler can help diabetics who have an aversion to injections.

Currently, the only way to limit insulin injections is to use an insulin pump which is a beeper-like device, worn on the hip, that attaches to a catheter implanted under the skin. But even pump-wearers require an injection every two to three days. The new insulin inhaler is in phase two clinical trials in several countries. If all goes well, the Food and Drug Administration could put it on a fast track for approval, making it available on the market in less than two years.

The reasons for not having the new insulin inhaler sooner are due to problems with proper dosage delivery, patient misuse, and overcoming complications like pneumonia, asthma, smoking, and chronic obstructive pulmonary disease (COPD). Ongoing patient trials will be analyzed to improve reliability of inhaled insulin to acceptable standards. The current research is to eliminate injections altogether, thus reducing the high fraction of those unwilling to take insulin because it`s associated with an injection.

mehr Infos:
http://www.techrumormill.com/mills/read.php?2,51,51#msg-51

[therman]

United States Awards Patent to Antigen Express Subsidiary of Generex Biotechnology

Thursday January 27, 11:43 am ET

Divisional Award in Ii-Key Hybrids Technology to Inhibit Antigen Presentation to Immunoregulatory T cells

TORONTO, Jan. 27 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News) announced today that its wholly owned subsidiary, Antigen Express, has received United States Patent US 6,835,382 B2 as of December 28, 2004. This award continues the divisional prosecution of an original application filed March 3, 1999. The specific award covers the use of Ii-Key peptide homologs to inhibit antigen presentation. It bears on potential treatments of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and diabetes mellitus.
Dr. Robert Humphreys, the Chief Scientific Officer of Antigen Express has spent his lifetime understanding how antigenic peptides are presented to the immune system and how novel treatments for disease might be designed. As a research fellow at Harvard University, he first isolated the MHC class II molecules, which present antigenic peptides to T helper cells, which regulate the immune response. He also discovered the immunoregulatory Ii protein that binds naturally into the antigenic peptide-binding site of those MHC class II molecules. He discovered a segment of the Ii protein, the Ii-Key peptide, which acts on MHC class II molecules to regulate peptide binding or exchange. Recently he and his colleagues at Antigen Express have discovered and patented novel hybrid peptides in which the immunoregulatory Ii-Key peptide is linked covalently to antigenic epitopes. By controlling the presentation of antigen peptides to the immunoregulatory T helper cells, new classes of drugs can be developed to enhance vaccines or to suppress autoimmune disease.

The Antigen Express compounds can either enhance or block presentation of antigenic epitopes to immunoregulatory T cells. In laboratory studies, such Ii-Key hybrids enhance presentation of the antigenic peptides 200-1000 times in test tube assays and make vaccines in animals about 10 times more potent. There are significant clinical and commercial potentials for these types of compounds as vaccines for cancer and infectious disease, and in diagnosing and suppressing autoimmune disease. Antigen Express has active research programs, some funded by the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the Department of Defense, for breast and prostate cancers and melanoma, and for infectious diseases such as influenza, smallpox, SARS and HIV.

In extension of the focus of Generex Biotechnology on the therapy of diabetes, Antigen Express scientists have applied their proprietary and patented techniques to develop novel diagnostics for type I or juvenile diabetes. Some individuals exhibit autoimmune reactions to various antigens associated with the pancreatic beta cells, which produce insulin in healthy individuals. The initial goal has been to identify persons who have such reactions prior to onset of frank disease, when the pancreatic beta cells have been destroyed by the autoimmune disease. As part of a long-range plan to develop novel therapies for diabetes mellitus, the types of inhibitor covered in this patent might come to be relevant. They might also come to be applied in treatments of rheumatoid arthritis or multiple sclerosis.

[therman]

Gute NEWS

Generex Biotechnology Corporation (ticker: GNBT, exchange: NASDAQ) News Release - 2-Feb-2005


--------------------------------------------------------------------------------
Generex Biotechnology Reports Preliminary Results of a Phase 2b Clinical Study of Oral-Lyn(TM)

Study Meets Primary Endpoint Demonstrating Oral Delivery of Insulin Has Pharmacokinetic And Glucodynamic Profiles Comparable to Injected Insulin
TORONTO, Feb 02, 2005 /PRNewswire-FirstCall via COMTEX/ -- Generex Biotechnology Corporation (Nasdaq: GNBT), a leader in the area of buccal drug delivery, today reported results of a preliminary Phase 2b clinical study of Oral-lyn(TM), the Company`s proprietary oral insulin spray formulation. The study showed, in a comparison of the postprandial glycemic control between the Oral-lyn(TM) regimen and injected regular human insulin, that Oral-lyn(TM) administered in a divided dose produces pharmacokinetic and glucodynamic profiles comparable to that produced by injected regular human insulin (administered in a divided dose for methodological consistency).

The primary objective of this open-label, single-center, active comparator trial was to equate the four-hour pharmacokinetic and glucodynamic profiles of (i) Oral-lyn(TM), given in a split dose around meals (five puffs before and after the meal), and (ii) injected regular human insulin (0.05 IU/kg), also provided, for methodological reasons, in a split dose before and after the meal. The study involved 10 patients with Type-1 Diabetes Mellitus (average age = 31.8) on multiple daily insulin injections (for an average of 11.4 years). Patients received either (1) Oral-lyn(TM) as a dose split equally between two administrations immediately before and after a standardized meal, or (2) regular human insulin injected in a dose split equally between two administrations before and after the test meal.

With its very fast onset and offset of action, Oral-lyn(TM) is predicted to carry less risk of hypoglycemia during chronic use than conventional injected insulin therapy. Hypoglycemia is a life-threatening risk of injected insulin therapy and along with injections is the most important obstacle to achieving good metabolic control and reducing complications in patients who require insulin. The Company is currently optimizing the Oral-lyn(TM) dosing regimen with a view to the implementation of pivotal clinical trials.

Unlike various pulmonary delivery methods (in which a powdered or liquid insulin formulation is inhaled into and absorbed by the lungs), Oral-lyn(TM) is delivered as a fine spray to the buccal (oral) cavity via the Company`s proprietary Rapidmist(TM) delivery system. The result is rapid insulin absorption through the buccal mucosal lining of the mouth without pulmonary (lung) exposure. Oral-lyn(TM) thereby provides a safe, simple, convenient, fast, and flexible means of insulin delivery with the important advantage of a faster onset and off-set of glucose-lowering action than injected regular human insulin. Persistent glucose-lowering activity associated with injected insulin therapy may increase the risk of hypoglycemia.

Oral-lyn(TM)`s dosing flexibility will enhance the ability to optimally individualize insulin therapy in a safe and convenient fashion

[therman]

Hi,

Die positiven vorläufigen Daten der Phase IIb sind

meiner Meinung der Anfang von einem positiven News Flow

in diesem Jahr.

Wenn die News wie erwartet kommen, könnte dies den Kurs
deutlich nach oben katapultieren - bei gutem Verlauf auch mehrere 100%.

Ich hatte am 17.01.05 ein Gespräch mit Anna E. Gluskin, CEO von GNBT.

Was wir dieses Jahr noch erwarten können ist:

1. Zulassung von Oral-lyn in Lateinamerika im 1.Quartal.
2. Beginn der Vermarktung in Lateinamerika im Laufe des Jahres 2005.
3. Beginn der Phase III Studien für eine Zulassung in USA.
4. Gespräche für eine Zulassung in Deutschland u. Europa sind im Gange.
5. Gespräche mit einem Major Partner zur Vermarktung sind im Gange, u. a. auch mit Merck.

Merck wäre ein geeigneter Partner, denn sie haben noch kein
Produkt zur alternativen Insulinversorgung in ihrem Programm.

6. Gespräche mit weiteren Partnern zur globalen Vermarktung
von Oral-lyn sind im Gange.

Ob alle Punkte erwartungsgemäß ablaufen, bleibt natürlich abzuwarten.

therman

[YesNewsNow]

Generex Biotechnology Granted U.S. Patent for Buccal Delivery of Pain Relief Medications
Wednesday February 9, 11:00 am ET
Company expanding applications for its RapidMist(TM) drug delivery technology


TORONTO, Feb. 9 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News), a leader in the area of buccal drug delivery, today announced that it has been granted another United States patent. The patent entitled, "Pharmaceutical compositions for buccal delivery of pain relief medications", relates to a narcotic analgesic formulation delivered into the human body by way of the buccal mucosa in the mouth.
ADVERTISEMENT


The formulations covered by the patent are applications of the Company`s proprietary RapidMist(TM) drug delivery technology and are designed to deliver pain relief medications such as morphine and fentanyl in a safe, simple, fast, effective and convenient alternative to injections and tablets.

This patent demonstrates the versatility of the RapidMist(TM) drug delivery platform. The platform, initially applied to insulin (the Company`s proprietary oral insulin formulation, Oral-lyn(TM)), a large molecule drug, can also be applied to small molecule drugs such as morphine and fentanyl, thereby significantly increasing the number of indications for the platform.

"Our mission is to improve drug delivery by making it simpler, more comfortable and more effective, thereby refining and augmenting therapeutic applications and facilitating increased patient compliance," said Anna Gluskin, President and Chief Executive Officer of Generex.

The application of the RapidMist(TM) platform, the efficacy of which has already been supported by late stage clinical trials of Oral-lyn(TM), to pain relief and management drugs delivered by traditional means for many years should facilitate market access and licensing opportunities.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company`s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company`s proprietary RapidMist(TM) device. The Company`s flagship product, oral insulin (Oral-lyn(TM)), is in late stage clinical trials around the world.

This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward- looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward- looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.




--------------------------------------------------------------------------------
Source: Generex Biotechnology Corporation

[therman]

Generex Biotechnology Granted U.S. Patent for Buccal Delivery of Pain Relief Medications
Wednesday February 9, 11:00 am ET
Company expanding applications for its RapidMist(TM) drug delivery technology


TORONTO, Feb. 9 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News), a leader in the area of buccal drug delivery, today announced that it has been granted another United States patent. The patent entitled, "Pharmaceutical compositions for buccal delivery of pain relief medications", relates to a narcotic analgesic formulation delivered into the human body by way of the buccal mucosa in the mouth.

The formulations covered by the patent are applications of the Company`s proprietary RapidMist(TM) drug delivery technology and are designed to deliver pain relief medications such as morphine and fentanyl in a safe, simple, fast, effective and convenient alternative to injections and tablets.

This patent demonstrates the versatility of the RapidMist(TM) drug delivery platform. The platform, initially applied to insulin (the Company`s proprietary oral insulin formulation, Oral-lyn(TM)), a large molecule drug, can also be applied to small molecule drugs such as morphine and fentanyl, thereby significantly increasing the number of indications for the platform.

"Our mission is to improve drug delivery by making it simpler, more comfortable and more effective, thereby refining and augmenting therapeutic applications and facilitating increased patient compliance," said Anna Gluskin, President and Chief Executive Officer of Generex.

The application of the RapidMist(TM) platform, the efficacy of which has already been supported by late stage clinical trials of Oral-lyn(TM), to pain relief and management drugs delivered by traditional means for many years should facilitate market access and licensing opportunities.

[therman]

Generex Biotechnology Working on Vaccine Development Against Bioterror Agents
Thursday February 10, 9:02 am ET
Collaborates to Use Animal Models and Volunteer Samples to Test Activity Of Novel Smallpox Vaccine


TORONTO, Feb. 10 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News) announced today that its wholly owned subsidiary, Antigen Express, has established collaborations with Emory University and the Imperial College of London to develop a novel smallpox vaccine. The vaccine is based on proprietary Antigen Express technology employing modified peptide antigens to stimulate immunity. The collaboration brings together one of the pre-eminent investigators on vaccinia, Dr. Geoffrey Smith of the Imperial College, and the noted immunologist Dr. Rafi Ahmed of Emory University. Dr. Robert Humphreys, founder of Antigen Express, will coordinate the program at Antigen Express.

Antigen Express has developed proprietary technologies that dramatically enhance the immunogenicity of small fragments from viral or tumor-associated proteins. "This is a particularly attractive strategy in the case of bioterror agents such as smallpox," said Robert Humphreys, founder and Chief Scientific Officer of Antigen Express. "The manufacture of small peptides is trivial compared to whole virus and safety concerns are virtually negligible. We are excited and fortunate to be able to work with such distinguished individuals as Drs. Geoffrey Smith and Rafi Ahmed on this project."

The specter of a smallpox bioterror attack has pointed to the need for a safer smallpox vaccine. The frequency of adverse reactions to the existing vaccinia virus used for vaccination against smallpox is high enough as to prevent mass vaccinations. While attempts have been made at generating safer vaccines, none have been developed that are thought to be safe enough today for widespread use. Dr. Geoffrey Smith of the Imperial College of London has studied extensively the immunological responses to vaccinia and is a recognized leader in this field. His investigations have been instrumental both in identifying the key proteins to use as vaccines as well as model systems wherein to characterized potential vaccines.

Dr. Rafi Ahmed has a long-standing interest in the ability of the immune system to `remember` prior exposures to an infectious agent and respond appropriately to subsequent infections, focusing both on HIV and vaccinia. This is of particular interest in the context of Antigen Express technologies for stimulation of T helper cells, which have long been shown to play a key role in immunological memory and are critical in mounting a robust response. Antigen Express has demonstrated the potential of this technology in preclinical models and plans to begin clinical trials in patients with breast cancer during the first quarter of this year.

[tasmandevil]

Gibt`s irgendwelche "bad news" zu Generex oder warum stürtzt das Ding so ab.


tasmandevil

[tasmandevil]

Am 15.03.05 gibt`s den 10Q report.
Bin mal gespannt.

tasmandevil

[HetfieId]

Keine News aber das Ding geht ab!

[HetfieId]

[tasmandevil]

Hier geht`s demnächst ganz steil nach oben !



FOR IMMEDIATE RELEASE

APRIL 19, 2005



GENEREX BIOTECHNOLOGY &

UNIVERSITY CAMPUS BIO-MEDICO

ANNOUNCE PUBLICATION OF

ORAL INSULIN RESEARCH STUDY



Study shows Oral-lyn™ controls blood glucose levels in

patients with type 1 insulin dependent diabetes



TORONTO, Canada & Rome, Italy – April 19, 2005 – Generex Biotechnology Corporation (NasdaqSC: GNBT), a leader in the area of buccal drug delivery, and University Campus Bio-Medico, Rome, Italy today announced that an Oral-lyn™ research paper by internationally renowned diabetes investigator Professor Paolo Pozzilli, head of the Department of Endocrinology and Diabetes at University Campus Bio-Medico, will be published in the August or September edition of Metabolism Clinical and Experimental (Copyright © 2005 Elsevier Inc.), a peer-reviewed US medical journal.



The paper is entitled Biokinetics of buccal spray insulin in patients with type 1 diabetes. The objective of the study was to evaluate the metabolic effect of Oral-lyn™, the Company’s proprietary oral insulin spray formulation, compared with subcutaneous (injected) regular insulin in patients with type 1 diabetes.



The study compared glucose and insulin in 18 patients with type 1 diabetes treated with Oral-lyn™ or subcutaneous (injected) regular insulin before meals with measurements for four hours after administration. The study found no statistically significant differences between the two insulins in achieving good control of blood glucose levels. In addition, in a subset of three patients, pre-meal Oral-lyn™ was administered for two entire consecutive days and their glucose levels were monitored using the glucose sensor monitoring system, a device able to measure and register glucose levels every two minutes for a period of 72 hours. These patients showed remarkably good metabolic control over the three day period of observation in the course of their daily routines, including working and leisure activities. No episodes of hypoglycemia were recorded and the patients were satisfied with the Oral-lyn™ therapy.



This is the first publication demonstrating the Oral-lyn™ is able to replace subcutaneous insulin in treating patients with type 1 diabetes. University Campus Bio-Medico and other centres in Europe are poised to commence Phase III studies aimed at demonstrating that Oral-lyn™ can achieve optimal metabolic control evaluated via glycosylated hemoglobin, a well-known parameter for determining optimization of glucose metabolism.



“In the near future, I foresee Oral-lyn™ given at meal times to patients with diabetes, with intermediate/long acting insulin being administered subcutaneously overnight,” said Professor Pozzilli. “The advantage of Oral-lyn™ is its rapid onset of action which is very similar to recently introduced insulin analogues, thereby allowing patients with diabetes, particularly children, to be more flexible in their eating habits and leisure activities. The time has now come for a significant alteration in the way we treat our patients with diabetes.”



The study was co-authored by S. Manfrini, F. Costanza, G. Coppolino, M.G. Cavallo and E. Fioriti, all of University Campus Bio-Medico, and P. Modi (of Generex).



About Generex



Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist™ device. The Company’s flagship product, oral insulin (Oral-lyn™), is in various stages of clinical trials around the world.



For more information, visit the Generex Web site at www.generex.com.



Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," “forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.



For further information:



AT INVESTOR RELATIONS INTL:

Zack Noory

Vice President & Account Group Manager

Ph: 818-382-9718

[HetfieId]

good news!
und gleich gehts hoch!


Generex Biotechnology Collaborator Reports an Advance in Intra-Tumor Gene Therapy for Cancer
PR Newswire - April 21, 2005 09:00
Therapy based on a novel immune stimulation strategy cures up to 50% of mice inoculated with a prostate tumor


TORONTO, April 21, 2005 /PRNewswire-FirstCall via COMTEX/ -- Generex Biotechnology Corporation (Nasdaq: GNBT), a leader in the area of buccal drug delivery, announced today that an academic collaborator of its wholly owned subsidiary, Antigen Express, has published a paper showing that their patented reagents and technology induce a potent immune response to prostate tumor in a preclinical mouse model.

Dr. Gilda Gali Hillman, Ph.D., Associate Professor of Radiation Oncology at Wayne State University Medical School and the Barbara Ann Karmanos Cancer Institute, in Detroit, Michigan, demonstrated that a curative immune response is optimal with tumor irradiation preceding the Antigen Express gene therapy protocol. She also demonstrated that T-helper and T-cytotoxic cells are essential for the effect. The advance in this method comes from stimulating the immune system of the tumor-bearing host with novel antigenic epitopes specific for immunoregulatory T helper cells in a manner that is applicable to the clinic. Without that stimulation, outcome is significantly worse. This paper appears in the journal, Human Gene Therapy, volume 16, pages 187 to 199, 2005. The full abstract is available through http://www.ncbi.nlm.nih.gov/entrez/query.fcgi.

Antigen Express scientists have shown that cancer cells are robust vaccines when they express MHC Class II molecules, and the Ii (Invariant Chain) immunoregulatory protein is suppressed. Many cancer cells express MHC Class II molecules, or they can be readily induced to do so with interferon gamma or the MHC Class II transactivator. Endogenously synthesized antigens, which are transported into the endoplasmic reticulum for binding to MHC Class I molecules, are normally excluded from Class II binding because the invariant chain (Ii protein) blocks the MHC Class II antigenic peptide binding site. Upon suppression of Ii protein expression with antisense methods, an enhanced repertoire of tumor cell antigenic epitopes becomes presented. This approach works with either cancer cells manipulated in cultures, or directly in vivo upon injection of the Antigen Express gene constructs into the tumor. A major advantage of this gene therapy approach is that only a subpopulation of tumor cells needs to take up and express the therapeutic gene constructs. That subpopulation leads to stimulation of T helper cells, which activate and induce cytotoxic T cells to eradicate all tumor cells in the body.

[HetfieId]

[HetfieId]

+ 0.14 (15.38% )

[tasmandevil]

Und weiter gehts !!!!




MAY 10, 2005





GENEREX BIOTECHNOLOGY CORPORATION Chairman and CEO PROVIDES INSIGHT ON COMMERCIAL mARKETING AND SALE OF KEY PRODUCT AND

FUTURE GROWTH of company in Special

Letter to Shareholders



TORONTO, CANADA – May 10, 2005 – Generex Biotechnology Corporation (NasdaqSC: GNBT), a leader in the area of buccal drug delivery, today announced that it has issued a Special Letter to Shareholders in an effort to update existing Generex investors on the current status of the Company, and more importantly, management’s perspective on the Company’s future growth outlook. The text from the letter follows:



Dear Shareholder,



I am writing you today to bring you up-to-date on the progress of Generex Biotechnology and, in particular, to share some recent news that is truly exciting.



First, the news. As we announced earlier this month, Generex has just reached the most significant milestone so far in its history: The first approval for commercial marketing and sale of its key product, the Oral-lyn™ oral insulin spray formulation. The Ecuadorian Ministry of Public Health has given the go-ahead for sales of Oral-lyn™ for the treatment of both Type-1 and Type-2 diabetes.



Ecuador is a small country but a significant market for insulin formulations. According to the International Diabetes Federation, it has approximately 360,700 adult patients with diabetes. More than that, it offers the first opportunity to put Oral-lyn™ to widespread commercial use in a broad patient population. Accordingly, we are optimistic that the other countries in the Andean Community – Venezuela, Colombia, Peru and Bolivia – will follow suit and approve Oral-lyn™ by the end of this year. We also expect to be ready to start Phase III clinical trials of Oral-lyn™ in Canada and Europe later in 2005.





~ more ~

The green light in Ecuador is historic not only for Generex but for medicine in general. It marks the first approval for commercial sale, by anyone, of non-injectable insulin. Ever since the discovery of insulin by Dr. Frederick Banting and Charles Best in 1921, this life-saving drug has been delivered solely by injection. Almost a decade of research and development at Generex has led to the first regulatory approval of a more convenient, less injurious method in which Oral-lyn™ is delivered via Generex’ proprietary RapidMist™ device into the mouth, where it is absorbed with no lung deposition. Oral-lyn™ is the only alternative delivery insulin product that does not involve the deposition of insulin in the lungs and therefore, unlike inhaled insulin, does not give rise to the safety concerns associated with lung deposition.

Turning the Growth Corner

Generex is pursuing a number of other highly promising therapies, principally through its wholly-owned subsidiary Antigen Express. I will have more to say about these shortly. But first I would like to describe just what the commercialization of Oral-lyn™ will mean for you, the Generex shareholders.

Simply put, we will no longer be a development-stage company once we start generating significant revenue from commercial sales and the granting of territorial licenses with significant upfront license fee payments. We will be a true growth company, with potential for very rapid expansion of revenue over the next several years predicated upon further regulatory approvals. We will continue to carry out robust R&D with an eye to bringing new drugs and formulations to market, but we will be able to finance this work out of our own revenue rather than having to rely wholly on outside financing. Commercial sales are the first step in the chain of events every biotechnology company plans for: Sizable revenue, then positive operating cash flow, and then profitability.

How soon will we reach all those stages? I cannot predict the future, and there are certainly many challenges to be met before we can get there. I can describe the markets we are targeting, the revenue we can expect from hoped-for market share, and the costs we need to cover to operate in the black.

The worldwide revenue from Oral-lyn™ sales is potentially significant. According to the International Diabetes Federation, some 194 million adults worldwide were believed to have Type-1 or Type-2 diabetes in 2003. An even larger number, 314 million, were estimated to have pre-diabetes (impaired glucose tolerance), which leads to Type-2 diabetes in 40% to 50% of cases. In the U.S. alone, the American Diabetes Association puts the number of people with diabetes at more than 18 million.



Within the population of those with Type 1 and Type 2 diabetes, we estimate that about 7% have Type 1; all of them must take insulin in order to survive. Another 10% of the diabetic population has Type 2 and also must take insulin. The remaining 83% have Type 2 but do not use insulin (because of the aversion to injections), at least not yet. Therefore,



~ more ~



about 17% of the 18 million diabetics in the U.S. – more than 3 million -- would be in the

potential market for non-injected insulin. The global market would be nearly 33 million. However, we are optimistic that a new paradigm of diabetes treatment will be established by the availability of Oral-lyn™, a safe, simple, fast, flexible and effective alternative to injected insulin, whereby patients with Type-2 diabetes who avoid insulin injections and patients with pre-diabetes impaired glucose tolerance and those with “The Metabolic Syndrome” (high lipids, hypertension, coronary artery disease) will elect to stave off the onset of more advanced diabetes and the associated complications (such as amputation, retinopathy, cardiovascular disease, nephropathy, neuropathy and peripheral vascular disease) by using Oral-lyn™ as an early preventative therapeutic measure; the consequent market for Oral-lyn™ could be as large as 600 million users.



In the near term, we have set a goal of 2.2% market share in the Andean Community within the first year after approval in each country, or 14,000 patients out of 600,000 insulin-using patients with diabetes. If we reach that mark, we would have annual sales of up to $14.5 million based on our current pricing model. Based on that model, we then would need to sell to about 1 million patients to hit $1 billion in sales. We could do this by gaining slightly over 30% of the U.S. market of insulin users, but we would need only 3% of the worldwide market to reach the same sales goal. If we achieve no greater market percentage than the 2.2% we have set as a one-year target in our initial markets, we would have nearly 700,000 global customers, producing annual revenue of about $700 million, without taking into account the expanded use of Oral-lyn™ by patients with Type-2 diabetes and impaired glucose tolerance who do not now take insulin injections.

We would not hit such levels immediately, but it’s not hard to see how we could quickly pay for our current and anticipated operating costs. In the past four quarters (through January 31, 2005, the midpoint of our fiscal year), we recorded $22.92 million in operating expenses, of which $11.12 million was for R&D and $11.81 million was for selling, general and administration costs. With biotechnology gross margins averaging just under 70% (according to recent data from Reuters), we would meet those expenses with revenue of just under $33 million, or what might be expected from just over 30,000 patients using Oral-lyn™. Expenses will rise as our business expands, but sales will rise much faster.

Science Moves Forward at Antigen Express

In addition to the development (and now marketing) of oral insulin, Generex is working on immune-response technologies for the treatment of cancer as well as infectious, allergic and auto-immune diseases. Our venue for this research is Antigen Express, which we acquired in August, 2003.







~ more ~



Antigen Express has reported a number of significant events recently. In April 2005, a novel therapeutic vaccine it has developed to stimulate an immune response to HER-2/neu was given for the first time to breast cancer patients in a trial at Walter Reed Army Medical Center in Maryland. That same month, a Michigan-based researcher working with Antigen Express published a study showing that patented Antigen Express reagents and technology produced a strong immune response to prostate tumors in mice. In Australia, it has just received a patent for the use of vaccine peptides in controlling cancer and infectious diseases, with a particular focus on the pandemic H5N1 influenza – known as “bird flu” -- which has been reported in Southeast Asia. Antigen Express is also continuing its work to develop a diagnostic kit to identify persons in the earliest stage of the autoimmune process leading to Type-1 diabetes.



As with all development-stage activity, it is difficult to say where these research avenues may lead us and whether they will lead to marketable products. But we can say this much: Success in biotechnology is built on vigorous science, and the science at Antigen Express fits that description. Coupled with the continued work on buccal drug delivery at the parent firm, the immuno-therapeutics research at Antigen Express puts Generex in a good position to develop new technologies that address the needs of large, global markets.



Stock Market Issues



Some of you have expressed concern about our ability to remain listed on NASDAQ because our stock price has been less than $1.00. Because the minimum bid price for our stock has remained below $1.00, we do expect to receive further notice from NASDAQ at the end of this month seeking to de-list Generex from the SmallCap Market, in which event the stock will be traded on NASDAQ’s over-the-counter bulletin board.



When we receive the notice, we will have the right to appeal the decision to a NASDAQ Listing Qualification Panel and will do so. Pending the decision of the Listing Qualification Panel, Generex common stock will continue to trade on NASDAQ. As you can see, our stock price has rebounded significantly since the announcement of Oral-lyn’s™ approval in Ecuador. The time period of the appeal will provide an opportunity for this information to continue to build momentum in our stock price, and the opportunity for the market to react to potential new announcements. If our stock price has not reached $1.00 for a sufficient period of time prior to our hearing with the panel but remains at current levels or above, we will make a strong case to the Panel to allow additional time.



It has been nearly 10 years since Generex got its start. During that time, investors had to keep a long-term view as the process of research, testing and regulatory approval slowly moved forward. Now that the economic payoff for that patience may be in sight, though, for many of us, the excitement of science has been a reward in itself. As we go forward into the commercialization and growth phase of our evolution, we intend to keep science foremost – to keep pushing ahead with new discoveries and new technologies – so that Generex can continue to augment shareholder value by bringing more products and improved health to the world. We deeply appreciate your interest in us and your willingness to invest in our shared future. We believe that, for you as well as for us, the best is truly yet to be.



Yours truly,



Anna E. Gluskin

Chairman, President and Chief Executive Officer



If you would like to be added to Generex’s investor email lists please contact Zack Noory with Investor Relations International at [e-mail].



About Generex



Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist™ device. The Company’s flagship product, oral insulin (Oral-lyn™), is in late stage clinical trials around the world. Generex acquired Antigen Express in August. 2003. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.





Cautionary Statement

Obviously, there are many logistical, regulatory and financial issues which must be successfully addressed in order for Generex to approach the potential success outlined above. Our statements regarding potential approvals, revenues and results should not be taken as predictions, but as management’s analysis of what may occur if our assumptions are correct. These statements are not guarantees of future results or events, and you should avoid treating them as predictions. As in any business, particularly one with new technologies and products, many factors and risks, both known and unknown, could prevent Generex from meeting its goals. Please review our SEC filings for some of the known risks and uncertainties. In particular, Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence



~ more ~





any phase of trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any “phase” of clinical trials.



Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.




For further information:

AT INVESTOR RELATIONS INTL:

Zack Noory

Vice President & Account Group Manager

Ph: 818-382-9718

[e-mail]

[tasmandevil]

GENEREX BIOTECHNOLOGY COMPLETES

ACQUISITION OF CUSTOM-MADE, FULLY-AUTOMATED EQUIPMENT FOR COMMERCIAL ORAL-LYN™ PRODUCTION



TORONTO, Canada – August 4, 2005 – Generex Biotechnology Corporation (NasdaqSC: GNBT), a leader in the area of buccal drug delivery, today announced that it has completed the acquisition of the custom-made, fully-automated equipment necessary to facilitate its initial commercial production of Oral-lyn™, the Company’s proprietary oral insulin spray product, which is delivered into the human mouth by way of the Company’s proprietary RapidMist™ drug delivery system.



Oral-lyn™ has been approved for commercial marketing and sale by the Ecuadorian Ministry of Public Health for the treatment of both Type-1 and Type-2 diabetes. The Company, together with its South American joint venture partner PharmaBrand, S.A. (www. pharmabrand.com.ec), is making preparations for the launch of commercial sales.



The equipment will allow Generex to produce up to 750,000 proprietary valves for its RapidMist™ device annually. The equipment, which includes molds and stamping tools, has been acquired from Valois of France (www.valois.com), a leader in the design and manufacture of spray and delivery systems. The consequent economies of scale will result in a significant decrease in the Company’s cost-of-goods.



The equipment includes:



- 4 molds (upper & lower stem, chamber, body)

- 3 gasket stamping tools (1st, 2nd, neck gaskets)

- ferrule stamping tool

- metal stem tool

- assembly line



The acquisition of this equipment will augment the Company’s ability to service the demand for Oral-lyn™ following the launch of commercial sales in Ecuador later this year. Based on the Company’s current pricing model and its current estimates of prospective market share, Generex anticipates that this equipment will produce approximately $3 million in gross revenue over the 18 months following product launch. The Company and PharmaBrand are also preparing to file materials for the approval Oral-lyn™ by the other Andean Community countries and this equipment acquisition will allow Generex to service commercial sales in those markets as well.



This scale-up of production components signifies the first steps towards the establishment of a new industry: the production of aerosolized proteins.



About Generex



Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist™ device. The Company’s flagship product, oral insulin (Oral-lyn™), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.



For more information, visit the Generex Web site at www.generex.com.



Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," “forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

# # #

[hallodu_st]

Weiß irgendjemand warums da heute abgeht????

[tasmandevil]

Deswegen wahrscheinlich



MICE WITH HUMAN ANTIGEN PRESENTING MOLECULES DEMONSTRATE STRONG RESPONSES TO NOVEL MELANOMA PEPTIDE VACCINE WHICH IS DESTINED FOR CLINICAL TRIALS



PAPER ON NOVEL CANCER VACCINE FROM GENEREX BIOTECHNOLOGY IS PUBLISHED IN PRESTIGOUS JOURNAL OF IMMUNOTHERAPY



TORONTO, Canada – August 23, 2005 – Generex Biotechnology Corporation (NASDAQ: GNBT) announced today the publication of a milestone paper in the prestigious cancer research journal Journal of Immunotherapy. This paper reports a late preclinical step in validating a novel melanoma vaccine for clinical trials. Parallel peptides containing MHC class II epitopes of the HER-2/neu antigen are in trials with patients with breast cancer.



Nikoletta Kallinteris is the leading scientist and first author of this paper entitled: “Insertion of melanoma gp100(48-56) epitope into the Ii-Key/MHC class II epitope hybrid peptide enhances CD4+ T cell responses in HLA-DR*0401 transgenic mice.” This paper reports her work of the past two years on a novel concept in melanoma vaccination. The model uses a special type of mouse in which human antigenic epitope presenting molecules have been introduced genetically, with suppression of the comparable mouse molecules. By these means, the mice more closely model the human immunological situation.



Lea Kallinteris explained that cancer clinicians in many academic cancer centers have shown that peptide vaccines offer significant hope for immunotherapies in patients with established and potentially recurrent cancers. Melanoma is one of the most advanced models for identification and use of such peptide vaccines.



She further explained that many vaccine peptides have been developed for stimulation of patients` cytotoxic T lymphocytes to kill cancer cells. However, clinical trials with such vaccine peptides do not demonstrate particularly robust results. The reason for this lack of potency stems in part from the fact that those vaccine peptides do not boost T helper cells, which up-regulate the cytotoxic T lymphocytes and provide long-term immunological memory.



Antigen Express scientists had developed a novel method to stimulate T helper cells with a hybrid vaccine peptide linking the peptide recognized by T-helper cells through a simple chemical linker to an immunoregulatory segment of the Ii-protein (the Ii-Key peptide). MHC class II epitopes in such Ii-Key hybrid peptides are presented 200 times more effectively than the epitope-only peptide in vitro. In this paper Lea Kallinteris demonstrated a potent boost of response in immunized mice.



Dr. Eric von Hofe, President of Antigen Express said, “I am very pleased with the progress made by Lea Kallinteris and her colleagues in this technically very difficult study. She has obtained clear demonstration of the power of this technology in cancer vaccines and obtained convincing data in an advanced preclinical model. This offers good support for an Investigational New Drug (IND) filing to the FDA for clinical trials.”



Anna Gluskin, CEO of Generex Biotechnology, said, “This is a significant recognition of our scientists by the official Journal of the International Society for Biological Therapy of Cancer, which is governed by the principal cancer immunotherapists of the world. We have a platform of vaccine products for treatment of major diseases. In cancer, our focus is in breast and prostate cancers, melanoma and colorectal cancer. In infectious diseases our focus is on HIV and Asian bird influenza. We have had continuing discussions about these programs with major companies, toward how best to advance these technologies into clinical trials.”



About Generex



Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist™ device. The Company’s flagship product, oral insulin (Oral-lyn™), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.



For more information, visit the Generex Web site at www.generex.com.

[hallodu_st]

Merci!

[hallodu_st]

Wird ja wieder, heute +16 % in Amiland

[therman]

Antigen Express, eine Tochterfirma von GNBT hat Patente zur Entwicklung eines Impfstoffes gegen die Asiatische Vogelgrippe. Alle Kräfte werden jetzt auf die Entwicklung eines Impstoffes konzentriert. Die Technologie ist neuartig und besser als die bisherigen Impfstoffe.
Allein dieses Feld ermöglicht längerfristig eine Vervielfachung des Aktienkurses.


News:

OCTOBER 19, 2005

GENEREX BIOTECHNOLOGY TO ACCELERATE DEVELOPMENT OF VACCINE FOR PANDEMIC AVIAN INFLUENZA
Novel vaccine technology boosting T helper cell response to Asian bird flu influenza promises increased population protection



TORONTO, Canada – October 19, 2005 – Generex Biotechnology Corporation (NasdaqSC: GNBT) announced today that Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, has re-organized its forces to speed development of a novel vaccine to protect against the H5N1 avian influenza. In particular, the President of Antigen Express, Eric von Hofe, will focus his efforts and those of the company on bringing this new vaccine into the clinic in the shortest time possible. A similar vaccine peptide, designed using a portion of a protein expressed in breast cancer cells modified with Ii-Key, is currently in clinical trials at the Walter Reed Army Medical Center.



“The threat of a pandemic by avian influenza has made it clear that yesterday’s vaccine technologies are woefully insufficient,” said Eric von Hofe, President of Antigen Express. “The vaccines being developed at Antigen Express have a clear role to play in responding to threats posed by agents such as H5N1 influenza.”



A major drawback to current vaccine development efforts is the inability to manufacture enough vaccine in the event of an avian flu pandemic. Current estimates are that the total production capacity of the world for producing an avian flu vaccine using traditional methods is less than 40 million doses, at the cost of several 100 million dollars. A compounding problem in developing vaccines for the avian flu is that two doses are required to achieve protective immunity given that people have never been exposed to a flu virus similar enough to impart even partial immunological protection. Further, they can be produced in nearly limitless quantities using entirely synthetic means in existing facilities.



The great advantage of the Antigen Express vaccine is the ability to expand and strengthen the T helper cell response to a lower dose of classically produced vaccine. The Ii-Key/H5 hybrids can be synthesized less expensively and in large quantities. It is also expected that the vaccine hybrids will afford some significant degree of protection in humans who have received no other vaccine.



Scientists at Antigen Express are developing a vaccine for the potentially pandemic Asian bird flu (H5N1 strain), utilizing highly conserved fragments of the H5 protein to stimulate potent T-helper cell activity. This is important, as a strong T-helper response plays a major role in helping the body to develop neutralizing antibodies to the influenza virus. The H5 fragments are modified using a portion of an immunoregulatory protein (termed Ii-Key) that greatly facilitates their ability to stimulate T-helper cell responses specific to the H5N1 strain. The vaccine peptides have been selected for their likelihood of being both potent and active in more than 80% of the population.



Antigen Express scientists designed and synthesized a panel of 24 Ii-Key/H5 hybrid vaccine peptides, using computer-modeling predictions to identify those with the greatest chance of being active in diverse populations. Recently completed studies demonstrated that T helper cells from mice immunized with recombinant H5 protein or H5 DNA responded strongly in INFγ and IL-4 ELISPOT assays to three Ii-Key/H5 hybrids, indicating that the natural response to H5 protein involved T helper cell recognition to three of the H5 peptides we had designed. Subsequent experiments demonstrated that immunization of mice with the three Ii-Key/H5 hybrids alone also lead to strong T cell responses.



About Generex



Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist™ device. The Company’s flagship product, oral insulin (Oral-lyn™), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.



For more information, visit the Generex Web site at www.generex.com.

[therman]

Die Atuelle Situation beflügelt den Kurs.

Heute plus 25% 1,10$

Kursziel längerfristig mindestens 10$.
Kurzfristig bis 2$.

Chart:

http://bigcharts.marketwatch.com/javachart/javachart.asp?sym…

[whyso]

Ein interessanter Vergleich, wer wird das Rennen um die Vogelgrippe letztendlich machen?

Es bleibt weiterhin spannend,
Whyso

[putin@ru]

aktie wird auf "strong by gesetzt " auf ntv seite 299 !

wer anrufen will !

[therman]

Die Nachrichten zur Vogelgrippe heizen den Kursanstieg
weiter an.

GNBT + 16%

Schlusskurs 1,26$

Kurzfristiges Ziel 2$.

Chart:http://bigcharts.marketwatch.com/javachart/javachart.asp?sym…

Nachrichten zur Vogelgrippe:
http://online.wsj.com/public/article/SB112896461663164579-pp…

Therman

[aischa1998]

die hat doch drüben schön angezogen

[therman]

Der Kursanstieg geht weiter!

Generex Biotechnology Presents Proposal to Interested U.S. Senators to Accelerate Development of Novel Pandemic Avian Influenza Vaccine
Thursday October 27, 12:15 pm ET


Company Seeks Congressional Support to Expedite Development of Its Avian Flu Vaccine


TORONTO--(MARKET WIRE)--Oct 27, 2005 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that senior representatives of the Company, together with executives of Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, presented a proposal today to interested senior senators to seek support for the accelerated development of its novel vaccine for H5N1 avian influenza.

The Company believes that the novel vaccine being developed at Antigen Express will be a valuable asset in combating avian influenza. The vaccine being developed is based on a proprietary platform technology whereby protein fragments (epitopes) from a novel antigen are identified and modified to enhance T helper cell stimulation. Activation of T helper cells has been shown to be essential in establishing an acquired immune response and in immunological memory. These features are particularly important in mounting an effective response to the potentially pandemic H5 strain of avian influenza.

"We believe we have made excellent progress in developing a novel vaccine to counter a pandemic avian influenza," said Anna Gluskin, President & Chief Executive Officer of Generex. "Our proprietary platform technology has been used to develop other immunotherapeutic vaccines that are currently in clinical trials, and we believe that the ease of manufacturing these vaccines and the urgent need to provide immunization merits congressional support for our activities. We are encouraged by the initial response to our proposal from these senior senators to help us in accelerating the development of our influenza vaccine."

Since the Antigen Express compound is a peptide, it can be manufactured easily and relatively inexpensively in any of a variety of existing manufacturing plants in large amounts. A serious limitation on most other proposed vaccines for H5 avian influenza is the inability to manufacture large quantities.

Antigen Express is developing other immunotherapeutic vaccines for cancer and infectious diseases using its proprietary technology platform enhancing T helper cell stimulation. The nature of the platform is such that any novel infectious agent can be analyzed rapidly for identification of MHC class II epitopes and subsequent modification for increased potency in stimulating T helper cells in an antigen-specific fashion.

[therman]

Generex Biotechnology Proposes Collaborations in China for the Co-Development of a Novel Vaccine for Pandemic Avian Influenza
Wednesday November 9, 9:10 am ET


Peptide-Based Vaccine Offers Easy Scale-Up and Flexibility in Preparing for Possible Pandemic Bird Flu Threat


TORONTO--(MARKET WIRE)--Nov 9, 2005 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, has made proposals for co-development of the Antigen Express novel H5N1 avian influenza vaccine in China following a trip to Beijing by Dr. Minzhen Xu, the Antigen Express Vice-President of Biology.

Proposals were made to: Professor Hualan Chen of the Harbin Veterinary Research Institute; Ms. Nan Wang, Vice General Manager of Sinovac Biotech Co., Ltd.; and Professor Bing Sun of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. All have an interest in vaccine development for the H5N1 avian influenza in China.

The vaccine technology being employed at Antigen Express for the potentially pandemic avian influenza is the same as that for its novel immunotherapeutic cancer vaccine currently in clinical trials. "The basis of this technology lies in identifying portions of a specific disease-associated protein that are capable of stimulating T-helper cells which are subsequently modified to augment their vaccine potency," explained Dr. Xu. "T-helper cells play a critical role in generating an immune response to a novel foreign agent, directing other immune cells against that threat, and in establishing immunological `memory` of that agent. Once these cells are stimulated, it is much easier to mount an effective response against an agent such as the H5N1 influenza virus."

Antigen Express has extant collaborations in China focusing on SARS and a novel immunotherapy strategy for patients with acute myeloid leukemia. "These relationships provide a convenient platform for expanding into avian influenza in China," said Dr. Eric von Hofe, President of Antigen Express. "The danger posed by avian influenza in China is more acute, given the recent outbreaks of the H5N1 strain in birds there, and they face the same supply limitations on traditional vaccines as are faced throughout the world. Furthermore, vaccinating people close to hot spots of H5N1 outbreaks is recognized as the best way to control a possible pandemic." Current estimates are that the world capacity per year for production of H5N1 vaccine by traditional methods would protect less than 40 million people.

Scientists at Antigen Express are developing a vaccine for the potentially pandemic Asian bird flu utilizing highly conserved fragments of the H5 protein to stimulate potent T-helper cell activity. The H5 fragments are modified using a portion of an immunoregulatory protein (termed Ii-Key) that greatly facilitates their ability to stimulate T-helper cell responses specific to the H5N1 strain. The vaccine peptides have been selected for their likelihood of being both potent and active in more than 90% of the population. This technology has the advantage of being applicable to any novel agent or protein once one has sequence information. As vaccine peptides are manufactured by entirely synthetic means they can be produced rapidly, relatively inexpensively, and in large quantities (hundreds of millions of doses).

[therman]

Hi
heute gehts ab bei GNBT

der Grund:

DJ Generex, Pharmabrand To Produce Oral Insulin For Lat Am

11/28/2005
Dow Jones News Services
(Copyright © 2005 Dow Jones & Company, Inc.)



QUITO (Dow Jones)--Canada`s Generex Biotechnology (GNBT) and Ecuador`s Pharmabrand SA will next year start production of oral insulin for export within Latin America.

With an initial investment of $22 million to manufacture the drug in Ecuador, "Oral-lyn," as the spray will be called, took Generex about 10 years to develop.

"We will be the first in the world to make it and the first to market oral insulin - first in Ecuador, and then progressively throughout Latin America," Pharmabrand President Roberto Cid told reporters.

Generex head Anna Gluskin said the company chose Ecuador given its strategic location, facilitating distribution of the drug throughout the region.

The Oral-lyn will be made in a Pharmabrand pharmaceuticals plant located in Quito, which is one of the most modern facilities in Ecuador.

The companies also hope to receive permission to sell the products elsewhere in Latin America, starting in the second half of next year. That includes selling first in Colombia, Venezuela, Bolivia and Peru, where common Andean region regulations exist, and then later in Brazil, Mexico, Chile and Argentina.

The companies forecast sales in all of Latin America of some $300 million a year.


-By Mercedes Alvaro, Dow Jones Newswires; 5939-9728-653; [e-mail]

[therman]

Hi ,

Verkäufe von Oralyn von 300Mill.

würde einen Aktienkurs von 10$ bedeuten.

Plus der Impfstoff für Vogelgrippe, und weitere Produkte......

Megapotential.

Wird aber weiterhin volatil bleiben.


Nur meine Meinung. therman

[therman]

Hi,

ich denke, der nächste Ausbruch bahnt sich an.


News:
Generex Biotechnology Announces Commencement of a New European Clinical Study of Oral-Lyn(TM) in Patients With Type-1 Diabetes
Tuesday January 10, 8:55 am ET


Study Conclusions to Be Included in Regulatory Submissions to Demonstrate New Diabetes Treatment Paradigm


TORONTO--(MARKET WIRE)--Jan 10, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, announced today that it has commenced a new European study of Oral-lyn, the Company`s proprietary oral insulin spray product, in patients with Type-1 diabetes mellitus. The study, entitled "A 12-Week, Open-Label, Randomized, Active Comparator Study of Oral-lyn(TM) Spray and Injected Human Insulin in Patients with Type-1 Diabetes Mellitus," will be undertaken at The Department of Endocrinology and Diabetes at the University Campus Bio-Medico in Rome, Italy under the supervision of internationally renowned diabetes investigator Professor Paolo Pozzilli, MD.
The Diabetes Control and Complications Trial (DCCT) demonstrated that an improvement in blood glucose levels reduces the risk of long-term micro-vascular complications in patients with type-1 diabetes. However, the DCCT also demonstrated that intensive subcutaneous (injected) insulin therapy results in an increased frequency of hypoglycemia such that ideal blood glucose control is not achieved. In addition, for many patients, the idea of multiple or intensive insulin use is undesirable because of the pain and inconvenience associated with injections.

To a large extent, sub-optimal glucose control and the risk of hypoglycemia are a result of the pharmacokinetic properties of subcutaneously injected insulin. Insulin absorption is strongly affected by local factors such as the site of injection, the depth of injection, the temperature and permeability of the tissue, and whether the underlying muscle is exercising or not. Furthermore, the pharmacokinetics of insulin are affected by the amount of insulin given, with large doses resulting in delayed time to peak effect and longer duration of action.

Although new monomeric insulin analogues may result in a more rapid onset and a shorter duration of insulin action, no practical method has been found to control the multiple variables affecting injected insulin absorption. The inability of injected insulin administration to effectively, reproducibly, safely, and painlessly control postprandial glucose levels has motivated Generex`s exploration of alternative methods of insulin delivery.

Generex has developed the RapidMist(TM) Diabetes Management System, which will be used to administer Oral-lyn. This system is based on a unique, proprietary formulation technology that provides a pain-free, needle-free, convenient method of administering insulin as a liquid pharmaceutical formulation delivered accurately into the mouth of the patient in the form of a spray. The fast-moving, fine particle aerosol easily traverses the thin membrane of the mucosal surface area of the oral cavity where it is absorbed into the blood stream and appears in the circulation within 10 minutes of the application of the spray. Oral-lyn(TM), as an Advanced Oral Drug Delivery platform, has a fundamental series of attributes: rapid access to the circulatory system; precise dosage control; simple self-administration procedure; and bolus drug delivery.

Previously published Phase 2 data from studies sponsored by Generex show that the speed of onset of the glucose-lowering response following Oral-lyn administration is consistent with that required for the achievement of postprandial glucose control. In particular, those studies demonstrated that Oral-lyn produces the desired rapid insulin uptake consistent that with required for dosing with a meal. Oral-lyn is a tasteless, liquid aerosol mist, which even after repeated administration, causes no irritation, burning, or discomfort in the mouth. In both long and short-term studies in patients with type-1 and type-2 diabetes undertaken in the USA, Canada, Europe, and South America, the onset of Oral-lyn action was earlier than that of subcutaneously injected insulin. Moreover, the studies demonstrated that Oral-lyn administration was successful in controlling postprandial glucose levels without relevant adverse events (no evidence of liver function changes, hematological changes, or severe hypoglycemia have been reported) and in the lowering of glycosylated hemoglobin (HbA1c) when compared to either standard subcutaneous injection therapy or oral agent therapy.

This new study of 60 adult patients with a history of type-1 diabetes mellitus in excess of one year and present intensive insulin therapy will evaluate the metabolic efficacy of Oral-lyn when administered at mealtimes in comparison to standard regular insulin therapy as measured by HbA1c. Following a baseline stabilization phase to determine optimal glargine and regular insulin doses, one group of patients will receive Oral-lyn in a split-dose fashion (half the dose immediately prior to the meal and the other half of the does immediately following the meal) at the optimal individualized dose. The other group of patients will receive regular insulin 30 minutes before meals and glargine insulin before the evening meal. All patients will remain on glargine therapy throughout the treatment period. Patients will consume regular meals and blood glucose levels will be measured four times each day (fasting level, before lunch, before dinner, and at bedtime).

[therman]

Vogelgrippe ist zur Zeit ein heisses Thema.
Bis die ersten Mittel auf den Markt kommen wird noch viel Zeit vergehen.
SVA Sinovac beginnt in China die klinischen Versuche mit ihrem Mittel, gefördert von der chinesischen Regierung.

Ob GNBT zum Zuge kommt bleibt abzuwarten, ich hoffe es gelingt.
Wann es zu dem Ausbruch der Vogelgrippe in großem Umfang kommt kann nicht vorausgsgt werden. Das kann Wochen, Monate oder noch eineige Jahre Dauern.

Bei dem Insulinprodukt Oral-Lyn beginnt gerade die Vermarktingsphase.

NEUE klinische Studie mit ORAL-LYN, dem Insulin Mundspray:

Generex Biotechnology Announces Commencement of a Long-Term Oral-lyn(TM) Clinical Study in Juvenile Patients With Type-1 Diabetes
Monday January 9, 9:58 am ET


TORONTO--(MARKET WIRE)--Jan 9, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, announced today that it has commenced a long-term (six month) study of Oral-lyn, the Company`s proprietary oral insulin spray product, in juvenile patients with Type-1 diabetes mellitus.

[therman]

Generex Biotechnology Announces Final Resolution of Sands Litigation
Friday January 13, 8:30 am ET


TORONTO--(MARKET WIRE)--Jan 13, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, announced today that on January 10, 2006 the Court of Appeals of New York denied a motion by Sands Brothers and Co., Ltd. for leave to appeal the January 23, 2001 and October 29, 2002 decisions and orders of the Appellate Division (First Department). The Appellate Division`s October 27, 2002 decision and order affirmed a lower court`s order vacating a New York Stock Exchange arbitration panel`s award granting Sands Brothers & Co., Ltd. a warrant to purchase 1,530,020 shares of the Company`s stock and modified that order by remanding the issue of damages to a new panel of arbitrators expressly limiting damages to reliance damages, which would not include damages for lost profits.
On August 17, 2004, the arbitration panel awarded Sands $150,000 in reliance damages, which award was confirmed by the lower court. In September 2005, Sands Brothers filed a motion seeking leave to appeal to the Court of Appeals of New York. The denial of Sand Brothers` motion lets stand the prior decisions and orders of the Appellate Division vacating the arbitration awards which had granted Sands Brothers a warrant to purchase the Company`s stock.

"The decision of the Court of Appeals of New York is a most welcome victory for Generex in this case," stated Anna Gluskin, President & Chief Executive Officer of Generex. "We have vigorously opposed Sands` claim in this case over the past 6 years and are grateful that our position has been vindicated."

[therman]

GNBT

hat auf wöchentlicher Basis ein Kaufsignal erzeugt.


Der nächste Schunb nach oben kann kommen.

therman

[tasmandevil]

Wird kommen


tasmandevil

[therman]

Hi,

hier zwei Aktien, die gerade am ausbrechen sind und das Potential haben sich in den nächsten Wochen zu vervielfachen, meiner Meinung nach.

Nanophase NANX
Nanogen NGEN

Am besten direkt an der US-Börse kaufen.


therman

[daktuell]

bloß hände weg von Nanogen

steht zwar "nano" drauf...ist aber nix drin!

[therman]

[posting]19.779.608 von daktuell am 19.01.06 09:30:52[/posting]Hi daktuell,

Ob man mit NGEN Geld verdient kommt auf das Timing an!!!
Zur Zeit ist Einstieg bei NGEN angesagt.
Der chart hat ein Kaufsignal erzeugt.

therman

[therman]

GNBT steig vorbörslich deutlich an auf Grund einer Meldung.

GNBT wird in Kanada die ZUlassung von Oral-lyn beantragen!!! Das ist der Hammer!!



Generex Biotechnology Announces Pre-NDS Meeting Scheduled for Generex Oral-lyn(TM) With Health Canada
Thursday January 19, 8:00 am ET


Company Will Seek to File a New Drug Submission in Order to Market and Distribute Generex Oral-lyn in Canada


TORONTO--(MARKET WIRE)--Jan 19, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, announced today that it has received notification of the scheduling of a Pre-NDS meeting for the Company with the Biologics and Genetic Therapies Directorate of Health Canada on March 1, 2006. The topic of the meeting will be Generex Oral-lyn, the Company`s proprietary buccal (oral) insulin spray product (no lung deposition). The Company believes this is the first non-injectable insulin to be the subject of a Pre-NDS meeting.

The purpose of the Pre-NDS meeting will be to discuss the presentation of Generex Oral-lyn data in support of a New Drug Submission (NDS). An NDS is an application submitted to Health Canada in order to market and distribute a drug product in Canada. Such applications are generally filed after clinical trials have been completed and all data has been collected and analyzed. This process is similar to a Pre-NDA (New Drug Application) meeting with the U.S. Food and Drug Administration.

therman

[therman]

Hier ein link zu ausserbörslichen Kursen in USA:

http://datasvr.tradearca.com/arcadataserver/JArcaBook.php?Sy…

[kobv]

[posting]19.785.098 von therman am 19.01.06 14:40:53[/posting]Heute bei NGEN eingestiegen.
Viel Erfolg.
Wo siehst Du Kursziel?

Grüße
kobv

[therman]

[posting]19.785.409 von kobv am 19.01.06 14:58:23[/posting]Ein konkretes Kurszielhabe bei NGEN habe ich nicht.

Ich erwarte ungefähr eine Verdoppelung in den nächsten Wochen.

Ich werde jedoch sofort verkaufen, wenn sich auf Grund des Wochencharts ein Verkaufsignal ergibt.

therman

[therman]

GNBT zur Zeit auf 1,10 $ ausserbörslich.

http://datasvr.tradearca.com/arcadataserver/JArcaBook.php?Sy…

[therman]

Mal sehen
vielleicht steuern wir jetzt die 2 Dollar an.

[therman]

Hi,

so wie es aussieht kann man in Canada möglicherweise
mit einem fast trak approval rechnen.

Lassen wir uns überraschen was die nächste Pressemeldung bringt.

therman

[therman]

sorry
es muss heissen fast track approval.

Charttechnisch deutet sich eine cup with handle Formation an.

Dies kann zusätzliche Aufmerksamkeit auf GNBT ziehen.

Cup with handle Formationen versprechen sehr große Kursanstiege.

Mal sehen.

therman

[kobv]

[posting]19.785.735 von therman am 19.01.06 15:16:00[/posting]NGEN charttechnisch noch bullisch?

Werde nächste Woche bei GNBT einsteigen.
Grüße
kobv

[therman]

[posting]19.806.512 von kobv am 20.01.06 18:24:30[/posting]Hi kobv,

ich trade NGEN auf wöchentlicher Basis und da stehen die Ampeln auf grün.
Für Daytrading habe ich zu wenig Zeit und das Trading auf wöchentlicher Basis ist effektiver. Man braucht weniger Trades und die Gewinne sind höher.
Kaufsignal wurde am 23.12.05 erzeugt und besteht weiterhin.
die momentane Konsolidierung ist wohl ein Pullback auf die überwundene 50 Tageslinie.

Bei GNBT wurde das Kaufsignal auf wöchentlicher Basis am 13.01.06 erzeugt und besteht ebenfalls noch.

Heute wird bei GNBT das Gap bei 0,98 geschlossen.

Ich halte weiterhin beide Werte.

Ich werde Dich hier an dieser Stelle informieren, wenn mein System ein Verkaufsignal auf wöchentlicher Basis liefert für GNBT und NGEN - was Du tust entscheidest natürlich Du selbst.
Das heißt ich werde dies spätestens bis montags vor US-Börseneröffnung hier einstellen.

Gruß

therman

[kobv]

[posting]19.809.688 von therman am 20.01.06 20:41:21[/posting]Danke im Vorraus, erfolgreiche Trades und schönes Wochenende.
Grüße

kobv

[therman]

Hi guten Morgen,

bei GNBT hat sich auf täglicher Basis ein Verkaufsignal ergeben, es könnte also nochmal bis 0,9 oder 0,8Dollar zurückgehen.
Auf wöchentlicher Basis besteht das Kaufsignal noch.

Bei NGEN hat auf täglicher und wöchentlicher Basis das Kaufsignal weiterhin bestand.

therman

[Gexe006]

Generex Biotechnology Announces FDA Pre-IND Meeting Scheduled for the Avian Flu Vaccine
Monday January 23, 7:30 am ET


Antigen Express Subsidiary Preparing to File IND Application


TORONTO--(MARKET WIRE)--Jan 23, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, will meet with the U.S. Food and Drug Administration (FDA) on February 10, 2006 to discuss requirements for the filing of an Investigational New Drug (IND) application for the novel Antigen Express vaccine to protect against the H5N1 avian influenza and the commencement of human clinical trials.
ADVERTISEMENT


A major drawback to current vaccine development efforts is the inability to manufacture enough vaccine in the event of an avian flu pandemic. Current estimates are that the total production capacity of the world for producing an avian flu vaccine using traditional methods is less than 40 million doses, at the cost of several hundred million dollars. A compounding problem in developing vaccines for the avian flu is that two high doses are required to achieve protective immunity given that people have never been exposed to a flu virus similar enough to impart even partial immunological protection.

The great advantage of the Antigen Express vaccine is the ability to induce a strong T-helper cell response using a synthetically manufactured peptide. This is important, as a strong T-helper response plays a major role in helping the body to develop neutralizing antibodies to viral infections. Because the Ii-Key/H5 hybrids can be manufactured synthetically, they are less expensive than cell-culture or hen-egg produced vaccines and it is possible to produce them in much larger quantities quicker in existing facilities. The induction of a good T-helper response is expected to greatly reduce the amount of classically produced vaccine necessary to achieve protective immunity. It is also expected that the Ii-Key/H5 vaccine hybrids will afford some significant degree of protection in humans who have received no other vaccine.

Scientists at Antigen Express are developing a vaccine for the potentially pandemic Asian bird flu (H5N1 strain) utilizing highly conserved fragments of the H5 protein to stimulate potent T-helper cell activity. The H5 fragments are modified using a portion of an immunoregulatory protein (termed Ii-Key) that greatly facilitates their ability to stimulate T-helper cell responses specific to the H5N1 strain. The vaccine peptides have been selected for their likelihood of being both potent and active in more than 80% of the population.

Antigen Express scientists designed and synthesized a panel of 24 Ii-Key/H5 hybrid vaccine peptides, using computer-modeling predictions to identify those with the greatest chance of being active in diverse populations. Recently completed studies demonstrated that T-helper cells from mice immunized with recombinant H5 protein or H5 DNA responded strongly in INF(gamma) and IL-4 ELISPOT assays to three Ii-Key/H5 hybrids, indicating that the natural response to H5 protein involved T-helper cell recognition to three of the H5 peptides we had designed. Subsequent experiments demonstrated that immunization of mice with the three Ii-Key/H5 hybrids alone also lead to strong T cell responses.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company`s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company`s proprietary RapidMist(TM) device. The Company`s flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex Web site at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Note to Editors: In the fifth paragraph, "(gamma)" is used to represent the gamma symbol, which cannot be transmitted over the wire.



Kann mal jemand kurz den Inhalt wiedergeben

[Gexe006]

Pre-Market (RT-ECN): 1.21 0.21 (21.00%)
Wow

[Gexe006]

schon Vorbörslich schöne Umsätze

top GNBT Stats Symbol Search


Time B/S Shares Price

8:02:29.808 S 1,200 1.1700

8:02:18.844 S 800 1.1700

8:02:04.834 B 48 1.1650

8:02:04.448 B 452 1.1650

8:02:04.448 B 48 1.1600

8:01:57.926 S 500 1.1500

8:01:57.354 B 1,500 1.1600

8:01:54.467 B 2,000 1.1600

8:01:52.396 B 500 1.1500

8:01:52.183 B 1,000 1.1500

8:01:52.183 B 500 1.1500

8:01:49.895 B 1,000 1.1500

8:01:47.494 B 1,500 1.1500

8:01:47.242 B 2,000 1.1500

8:01:47.242 B 1,500 1.1500

8:01:47.242 B 3,450 1.1480

8:01:37.840 S 1,000 1.1100

8:01:37.840 S 1,000 1.1100

8:01:18.368 B 500 1.1350

8:01:15.897 B 50 1.1480

8:01:15.303 B 500 1.1250

8:01:12.153 B 500 1.1480

8:01:08.622 S 800 1.1100

8:01:04.779 S 2,400 1.1100

8:00:39.325 S 10,000 1.1000

8:00:39.325 S 10,000 1.1000

8:00:39.325 S 4,000 1.1000

8:00:39.325 S 700 1.1000

8:00:39.325 S 1,000 1.1000

8:00:39.325 S 9,000 1.1100

8:00:17.639 S 500 1.1500

8:00:09.368 B 1,000 1.1500

7:57:23.114 S 1,000 1.0800

7:36:54.038 B 500 1.2100

[therman]

HI,

durch die Meldung über das FDA Meeting wegen Impfstoff gegen Vogelgrippe wird das Verkaufssignal auf Tagesbasis hinfällig.
GNBT möchte demnächst mit klinischen Versuchen mit dem Impstoff beginnen.

Hier ein link zu ausführlichen vor und nachbörslichen,
ausserbörslichen Realtimekursen:

http://datasvr.tradearca.com/arcadataserver/JArcaBook.php?Sy…

therman

[Gexe006]

Vorbörslich schon über 1,3 Millionen Aktien gehandelt
Pre-Market (RT-ECN): 1.25 0.25 (25.00%)

[Gexe006]

Pre-Market (RT-ECN): 1.32 0.32 (32.00%)

[Buddah]

schönes Volumen!

[therman]

Hi,

habe heute einen Teil verkauft zu 1,41 Dollar,
werde niedriger zurückkaufen.

Es ist mit einem Schließen des Gaps bei 1 Dollar zu rechnen in den nächsten Tagen.

therman

[therman]

Die gestrige tageskerze stellt ein verkaufsignal auf täglicher basis dar.

mit einem kursrückgang auf 1 dollar muss mit hoher wahrscheinlichkeit gerechnet werden.

therman

[therman]

Wie erwartet geht es bei GNBT heute weiter in Richtung
1 Dollar.

Das Verkaufssignal auf täglicher basis hat noch bestand.

therman

[therman]

GNBT präsentiert Zwischenergebnisse aus den klinischen Tests bei Brustkrebs.:


http://biz.yahoo.com/iw/060125/0107353.html

Generex Biotechnology Announces Interim Results of Clinical Breast Cancer Trials
Wednesday January 25, 8:00 am ET


Collaboration With Walter Reed Army Medical Center Demonstrates Good Response to Novel Peptide Vaccine


TORONTO--(MARKET WIRE)--Jan 25, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today interim results of an ongoing clinical trial designed to assess the safety and immunological potency of a novel peptide vaccine in patients with breast cancer. The therapeutic vaccine is being developed by its wholly owned subsidiary, Antigen Express.

[hooray1]

therman, hast du eine Ahnung, was den Markt an generex stört..?

bei jeder guten Meldung wird Kasse gemacht, aber summa summarum kommt das Ding nicht vom Fleck..

Danke und Gruß, hooray

[merx]

Generex to Discuss Bird Flu Vaccine With FDA
Jan 29, 03:22 AM


The immunotherapeutics unit of Canadian biotech Generex has arranged to meet with the FDA to discuss making an application for a new investigational bird flu vaccine.

Antigen Express, Generex`s wholly owned subsidiary, will meet with the FDA in February to discuss requirements for the filing of an investigational new drug (IND) application for the novel Antigen Express vaccine to protect against the H5N1 avian influenza and the commencement of human clinical trials.

Scientists at Antigen are developing a vaccine for the potentially pandemic Asian bird flu (H5N1 strain) utilizing highly conserved fragments of the H5 protein to stimulate potent T-helper cell activity. The H5 fragments are modified using a portion of an immunoregulatory protein (termed Ii-Key) that greatly facilitates their ability to stimulate T-helper cell responses specific to the H5N1 strain.

The vaccine peptides have been selected for their likelihood of being both potent and active in more than 80% of the population.

The great advantage of the Antigen vaccine over conventional vaccines is its ability to induce a strong T-helper cell response using a synthetically manufactured peptide. This is important, as a strong T-helper response plays a major role in helping the body to develop neutralizing antibodies to viral infections.

Because the Ii-Key/H5 hybrids can be manufactured synthetically they are less expensive than cell-culture or hen-egg produced vaccines and it is possible to produce them in much larger quantities quicker in existing facilities.

The induction of a good T-helper response is expected to greatly reduce the amount of classically produced vaccine necessary to achieve protective immunity. It is also expected that the Ii-Key/H5 vaccine hybrids will afford some significant degree of protection in humans who have received no other vaccine.

[whyso]

Wars das mit der Bewegung bei GNBT am vergangenen Freitag???
After Hours (RT-ECN): 1.18 0.09 (8.26%)

Ich werde entweder GNTA & NVAX nachkaufen, oder ein ganz neue Position GNBT eröffnen um die 0,75 cent

Der Thread hier ist jedenfalls gut versteckt, ich habe es nur gefunden dank ein link von die andere zwei Generex links gefunden...

Viele Grüße & good trades,
Whyso

[therman]

[posting]19.904.408 von hooray1 am 27.01.06 09:26:15[/posting]Hi hooray1,

ich kann nicht sicher sagen woran es liegt.

Vielleicht an der Vorgeschichte von GNBT.

GNBT hatte vor Jahren schon eine Cooperations und Vertriebsvereinbarung mit Eli Lilly für Oral-lyn.
Diese Vereinbarung wurde jedoch aufgelöst.
Diese löste den Niedergang der letzten Jahre aus.

Da GNBT ständig in finanziellen Schwierigkeiten steckte hat sich die Entwicklung von Oral-lyn immer mehr hinausgezögert.

Misstrauen auf Grund der Vorgeschichte oder aber shortselling.

Bis richtig Geld verdient wird mit dem Produkt wird noch einige Zeit vergehen.
Bis das Mittel zur Vogelgrippe entwickelt ist, dauert auch noch lange.

Der Kurs wird allein von der Phantasie auf künftige Gewinne getrieben, deshalb ist er so volatil.


Charttechnisch steht GNBT auf wöchentlicher Basis auf Halten, das Gap wurde am Freitag geschlossen.
NGEN steht ebenfalls auf Halten auf wöchentlicher Basis.


therman

[therman]

GNBT

in der Pharmapresse:

http://www.in-pharmatechnologist.com/news/ng.asp?n=65365-gen…

[therman]

Es sieht nach einer sehr starken Eröffnung aus heute.

vorbörslich jetzt bei 1,19$.

Das Gap ist geschlossen und die Warrants sind offensichtlich eingelöst, es kann wieder aufwärtsgehen,
das erwarte ich zumindest.

therman

[therman]

GNBT liefert soeben

ein starkes Kaufsignal auf täglicher basis.

Schließt der Kurs unter 1,15 $ dann wird dieses Kaufsignal
hinfällig.

therman

[hooray1]

[posting]19.953.592 von therman am 30.01.06 09:21:30[/posting]Hi therman,

super, danke für die Info!

[therman]

das kaufsignal wurde gestern klar bestätigt.

es sieht so aus als ob es jetzt richtig kräftig nach oben geht.

vorbörslich: 1,27$

therman

[Freeee]

HALLLLOOOO!!!!! Wieso ist hier fast niemand!!! Wo sind die ganzen Energulfer, Caspianer,Cobracrestler und Co.?? Leute, hier gibt´s bald was Dickes zu holen -WKN 922012 wird euch geruhsame Nächte bereiten!!!
Ich werde schon mal das Meinige dazu tun, damit die "Schlagzahl" erhöht wird: Ein ernst gemeintes, hoffnungsfrohes Lächeln

[Freeee]

[Freeee]

(doppelt hält besser!)

[therman]

[posting]19.979.417 von Freeee am 31.01.06 18:55:35[/posting]Hi Freee,

die Aktien die du erwähnst werden alle von vielen diversen Aktienbriefen gepuscht und die lemminge springen hinter her.

GNBT ist quasi noch unendeckt.

therman

[therman]

GNBT und NGEN

stehen charttechnisch beide weiterhin auf halten.

therman

[therman]

GNBT steht im tages und -wochenchart auf halten.

NGEN steh im wochenchart auf halten im tageschart auf neutral.
Bei NGEN geht kurzfristig die konsolidierung weiter, wobei
die nächsten unterstüzungen bei 2,90 und 2,82 $liegen.

therman

[therman]

GNBT

überwindet heute wichtige Widerstände.

Der große Anstieg kommt erst noch.

Weiter halten.

therman

[therman]

Nicht vergessen:
Am 10.ten Februar findet ein Treffen mit der FDA statt
wegen dem Impfstoff gegen Vogelgrippe.

TORONTO--(MARKET WIRE)--Jan 23, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, will meet with the U.S. Food and Drug Administration (FDA) on February 10, 2006 to discuss requirements for the filing of an Investigational New Drug (IND) application for the novel Antigen Express vaccine to protect against the H5N1 avian influenza and the commencement of human clinical trials.

[therman]

Heute plus 8,8% auf 1,35$

im vorfeld des FDA meetings dürfte der kurs weiter ansteigen.

langfristig sehe ich ein megapotential durch die innovative technologie für impfstoffe von Antigen Express
aber ebonso durch Oral-lyn.

kurzfristig weiter volatil.

heute wurden die widerstände bei 1,25 und 1,29$ überwunden .
nächster widerstand bei 1,36$.
es kann möglicherweise schnell bis auf 2$ gehen.

therman

[Xepher]

wow !!!! was für ein volumen hier in deutschland !!!! sowas gab es bei GNBT schon lange nicht.
bin schon lange drin...habe auch zum teil graue haare von der verdammten warterei.
. :
..aber es scheint als würde GENEREX schön langsam wach geküsst...
guckst du bei di link !!!

http://www.stockta.com/cgi-bin/analysis.pl?symb=GNBT&num1=8&…

[Xepher]

die amis drehen am berühmten rad....ha,ha,ha
shortys müssen sich eindecken
na dann...schnallt euch an...and enjoy the ride.

[therman]

wie erwartet treibt das meeting mit der FDA am freitag

die kurse im vorfeld nach oben.

GNBT erhofft sich ein funding=eine finanzielle förderung ihrer Versuchsreihen für den Impfstoff gegen die vogelgrippe.
Antigen Express die Tochterfirma von GNBT, die diesen Impfstoff entwickeln wird hat eine innovative Technologie, die einige entscheidende vorteile bietet.
Wenn es optimal läuft, dann bekommt GNBT einen fast track status für diese entwicklung.

therman

[Xepher]

habt ihr den anstieg der letzten minuten gesehen
wir werden morgen zuerst short eindeckung in deutschland und danach in USA sehen....gut so
laßt sie alle bluten
sorry ich habe all zu lang mit GNBT wegen diesen short-idioten gelitten....
endlich gehts wieder in die richtige richtung.
gute nacht und bleibt cool
THERMAN!!! danke für deine sachlichen und kompetente beiträge. ich habe sie immer mit vergnügen gelesen.
GNBT ist in deutschland noch weitgehend unentdeckt....ich hoffe es bleibt noch ein weilchen so.

gute n8
xepher

[therman]

GNBT legt 14% zu und schließt auf 1,54$.

dabei wurde ein gap auf gerissen.

mal sehen wie es morgen weitergeht.

therman

[Xepher]

ich glaube das morgen ein 2tes GAP aufgerissen wird

[therman]

[posting]20.090.480 von Xepher am 07.02.06 22:48:41[/posting]Ein weiter s gap halte ich auch für gut möglich.

Bei GNBT stehen die Ampel auf grün.

Widerstand bei 1,36 $ überzeugend überwunden.

therman

[Xepher]

hmmmm es kommt bei uns in FFM wieder bewegung rein...... die jenigen die bei ca 1,50$ aussteigen wollten haben es getan...... viele werden abwarten und steigen heute nach überwindung des ATH wieder ein.....FDA meeting ist erst am freitag.... news von dem meeting erwarte ich nicht sofort.....also sell on news wird hier nicht funktionieren. ich bin gespannt wo unser nächstes ATH sein wird

[Gexe006]

Pre-Market Trade Reporting Wednesday February 08


Pre-Market Last: $ 1.62 Pre-Market
High: $ 1.65 Pre-Market
Volume: 32,900 Pre-Market Low: $ 1.59

[frank55]

Kursziel im Aktionär 2,50 Euro

[therman]

[posting]20.115.867 von frank55 am 09.02.06 13:01:29[/posting]Ziel 2,5$ auf welchen Zeitraum.

Langfristig(mehrere Jahre) hat GNBT das Potential zum Verzehnfachen, meine ich.

@Xepher: Alltimehigh bei GNBT war:
24,875Dollar am 6.Sept. 2000.

die letzten zwei tage war konsolidierung angesagt.
mal sehen was morgen passiert.

therman

[frank55]

[posting]20.123.165 von therman am 09.02.06 19:21:55[/posting]Ziel sind immer 12 Monate,bezüglich des Vogelgrippeimpfstoffes hat man nicht das Geld,um einen kommerziellen Imstoff zu entwickeln,man braucht einen grossen Partner.

[Xepher]

danke therman

sorry ( ich depp) ich meinte das 52 week high...glaube das war bei 1,51 $ oder?
nun wir werden heute sehen... wobei ich fast glaube das die amis das GAP 1,37$-1,39$ schließen..... .
auf jeden fall werde ich GNBT die nächsten tage schärfer beobachten wie sonst. ...und im gegebenen fall nachkaufen

[Xepher]

GAP zu!! los gehts

[Xepher]

na dann eben später...oder

[therman]

[posting]20.136.564 von Xepher am 10.02.06 15:17:58[/posting]genau xepher 52high war 1,51 im oktober 2005.

Das gap ist zu,
unterstützung bietet heute die 10-tageslinie, bei ca. 1,36. mal sehen ob ie hält.

@ frank 55:
Wenn GNBT eine finanzielle Förderung vom Staat für die Entwicklung des Vogelgrippeimpfstoffes bekommen brauchen sie nicht unbedingt einen Großen Partner der die Kosten übernimmt. die chancen für eine förderung stehen gut, denn Bush hat gesagt, dass er die entwicklung eines Impstoffes mit fördemitteln beschleunigen will.

Anna Gluskin CEO von GNBT, ich habe mit ihr schon telefoniert, geht nur dann eine Partnerschaft mit einem "Großen" ein, wenn sie ihre Bedingungen durchsetzen kann, das heißt, wenn GNBT gut dabei verdienen kann.

Aus diesem Grunde ist die ehemalige Partnerschaft mit Eli Lilly damals geplatzt.

therman

[rhynno]

Hat schon jemand was von der gestrigen Verstellung bei der amerikanischen FDA bezüglich des Vogelgrippe Medikaments ???

[BreX]

Vogelgrippe weitet sich aus...nun auch in der EU:

Erstmals ist das auch für Menschen gefährliche Vogelgrippe-Virus H5N1 in der Europäischen Union nachgewiesen worden. Infizierte Schwäne haben das Virus nach Sizilien und Griechenland getragen."

http://stern.de/wissenschaft/medizin/:Vogelgrippe-H5N1-Itali…

[rhynno]

Vogelgrippe breitet sich auch in Nigeria wie ein "Buschfeuer" aus. Einfach mal nach googeln Bin mal gespannt was uns die nächsten Woche so bringen !

[BreX]

http://www.ceocast.com/(vyerbi55ycvnsba0bhr5sc45)/NewsLetter…

12.2.06

New 52-week high: Shares of drug delivery company Generex Biotechnology Corporation (NASDAQ: GNBT), reached a new 52-week high of $1.64 as investors anticipated a positive outcome for the company’s wholly-owned subidiary Antigen Express, Inc.’s meeting with the U.S. Food and Drug Administration that happened last Friday.

The topic of the meeting was to discuss requirements for the filing of an Investigational New Drug (IND) application for the novel Antigen Express vaccine to protect against the H5N1 avian influenza and the commencement of human clinical trials. The avian flu pandemic has been constantly grabbing headlines creating investor interest in companies that offer solutions in the event of an avian flu pandemic. Shares closed the week at $1.41, up 17 cents on strong volume.

[therman]

Bis jetzt noch keine Meldung über das FDA Meeting.

Charttchnisch steht GNBT weiter auf Halten.

Am Freitag wurde die 10-SMA täglich angetestet.

NGEN steht im wochenchart weiter auf halten.

therman

[frank55]

Generex Biotechnology Completes Positive Pre-IND Meeting With FDA for Its Avian Flu Vaccine Antigen Express Subsidiary Preparing for IND Filing

TORONTO, Feb 13, 2006 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that on February 10, 2006, Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, concluded a positive Pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding plans for the commencement of clinical trials of the proprietary and innovative Antigen Express vaccine to protect against the H5N1 avian influenza.
As a consequence of the Pre-IND meeting, Antigen Express has clarified the development path (including clinical study design) and regulatory timetable for its innovative vaccine. Prior to the submission of its IND, Antigen Express will conduct a toxicology study and a pre-clinical study to establish the vaccine`s dosing regimen.

"We are very pleased with the outcome of our meeting with the FDA," said Dr. Eric von Hofe, President of Antigen Express. "We appreciate the extent to which the FDA will be engaged in this process and we look forward to its continuing guidance. We feel that this early intercession with the FDA will streamline our developmental and regulatory processes."

The Antigen Express avian influenza vaccine is based on a platform vaccine technology presently in human clinical trials in the form of a breast cancer vaccine. The breast cancer vaccine clinical trials are being undertaken at Walter Reed Army Medical Center (WRAMC), and a representative of WRAMC participated in this avian flu vaccine Pre-IND meeting with Antigen Express.

The Antigen Express vaccine is designed to induce a strong T-helper cell response using a synthetically manufactured peptide. A strong T-helper cell response plays a major role in helping the body to develop neutralizing antibodies to viral infections. Because the vaccine can be manufactured synthetically, it will be less expensive than cell-culture or hen-egg produced vaccines and it is possible to produce it in much larger quantities and much quicker using existing facilities. The induction of a good T-helper response is expected to greatly reduce the amount of classically produced vaccine necessary to achieve protective immunity in prime/boost regimens. The study will also attempt to establish whether application of the vaccine on its own will provide a significant degree of protection in humans who have received no other vaccination.

An Investigational New Drug Application (an "IND") is documentation that must be submitted to the FDA before a new drug (or biologic) can be used for human testing. The documentation includes evidence that the compound is biologically active and is safe for initial administration to humans in clinical investigations (i.e. pre-clinical efficacy, safety tests, pharmacology, dose ranging, manufacturing procedures, proposed first protocol). An IND is subject to an automatic 30-day review period.

Pre-IND meetings are conducted with the appropriate FDA review division that would review the drug marketing application (in this instance, the Center for Biologics Evaluation and Research) and these meetings are requested by the sponsor of a drug. Meetings at this stage in the process are useful opportunities for open discussion about testing phases, data requirements, and any scientific issues that may need to be resolved prior to IND submission.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company`s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company`s proprietary RapidMist(TM) device. The Company`s flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

[nekro]

Vorbörslich schon + 20 %

[therman]

Eine weitere Nachricht:

Generex Biotechnology Announces Final Resolution of Sands Litigation
TORONTO -- (MARKET WIRE) -- 01/13/2006 -- Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today that on January 10, 2006 the Court of Appeals of New York denied a motion by Sands Brothers and Co., Ltd. for leave to appeal the January 23, 2001 and October 29, 2002 decisions and orders of the Appellate Division (First Department). The Appellate Division`s October 27, 2002 decision and order affirmed a lower court`s order vacating a New York Stock Exchange arbitration panel`s award granting Sands Brothers & Co., Ltd. a warrant to purchase 1,530,020 shares of the Company`s stock and modified that order by remanding the issue of damages to a new panel of arbitrators expressly limiting damages to reliance damages, which would not include damages for lost profits.

On August 17, 2004, the arbitration panel awarded Sands $150,000 in reliance damages, which award was confirmed by the lower court. In September 2005, Sands Brothers filed a motion seeking leave to appeal to the Court of Appeals of New York. The denial of Sand Brothers` motion lets stand the prior decisions and orders of the Appellate Division vacating the arbitration awards which had granted Sands Brothers a warrant to purchase the Company`s stock.

"The decision of the Court of Appeals of New York is a most welcome victory for Generex in this case," stated Anna Gluskin, President & Chief Executive Officer of Generex. "We have vigorously opposed Sands` claim in this case over the past 6 years and are grateful that our position has been vindicated."

[therman]

[posting]20.179.867 von therman am 13.02.06 14:19:02[/posting]Sorry,

das war eine schon etwas ältere Meldung.

Vorbörslich weiter im Plus.

Eröffnung vermutlich mit GapUp.

Meistens werden die Gap-ups geschlossen.
Werde deshalb eventuel einen Teilverkauf machen,
um dann billiger zurückzukaufen.
Aber erst mal beobachten.

therman

[therman]

Charttechnisch steht GNBT weiter auf halten.

Eine Konsolidierung scheint sich anzukündigen.

Auf Grund der aktuellen Situation ist der Kurs heute in Deutschland angestiegen.
Mal sehen was morgen in USA passiert, denn dort werden die Kurse gemacht, der Kursverlauf in Deutschland ist irrelevant.

Typisch für GNBT wäre eine Starke Eröffnung und dann ein Kursrückgang.

therman

[jojobada]

Im USa Chart haben wir das langersehnte Kaufsignal im Chart. Dazu kommt ne W-Formation wie bei uns.

Wi ich schon schrieb, bin als Kind mal in ein Faß mit ganz vielen W´s gefallen. Kenne mich ganz gut damit aus.

Gruß jojobada der Wellenreiter. Immer auf und ab!

[therman]

[posting]20.295.341 von jojobada am 20.02.06 20:10:53[/posting]GNBT heute sehr stark.

die angedeutete Konsolidierung wurde nicht eingeleitet.
Noch keine Schwäche erkennbar, weiter halten.

Es wurde allerdings ein Gap aufgerissen, mal sehen ob es geschlossen wird, wie es bisher der Fall war.

nächster wichtiger Termin am 1.ten März:

Generex Biotechnology Announces Pre-NDS Meeting Scheduled for Generex Oral-lyn(TM) With Health Canada
Thursday January 19, 8:00 am ET


Company Will Seek to File a New Drug Submission in Order to Market and Distribute Generex Oral-lyn in Canada


TORONTO--(MARKET WIRE)--Jan 19, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, announced today that it has received notification of the scheduling of a Pre-NDS meeting for the Company with the Biologics and Genetic Therapies Directorate of Health Canada on March 1, 2006. The topic of the meeting will be Generex Oral-lyn, the Company`s proprietary buccal (oral) insulin spray product (no lung deposition). The Company believes this is the first non-injectable insulin to be the subject of a Pre-NDS meeting.

[jojobada]

Guten morgen @all

Generex Biotechnologie verkündet die Pre-NDS Sitzung, die für Generex festgelegt wird, das mit Gesundheit Kanada Donnerstag Januar 19, 8:00 morgens Mündlichist UND Firma sucht, eine neue Droge-Unterordnung einzuordnen, um Generex zu vermarkten und zu verteilen, das in Kanada Mündlichist TORONTO -- (market WIRE) -- Jan. 19, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - Nachrichten), ein Führer im Bereich der bukkalen Drogeanlieferung, heute verkündet, daß er Mitteilung der Terminplanung einer Pre-NDS Sitzung für die Firma mit dem Biologics und genetischen dem Therapie-Direktorat der Gesundheit Kanada an März 1, 2006 empfangen hat. Das Thema der Sitzung ist Mund-lyn Generex, das Insulin-Sprayprodukt der Firma eigene bukkale (Mund) (keine Lungenflügelabsetzung). Die Firma glaubt, daß dieses das erste nicht-injizierbare Insulin ist, zum das Thema einer Pre-NDS Sitzung zu sein.

[therman]

Heute setzt eine Konsolidierung ein, mal sehen wie weit sie führt.

Bei dem Meeting mit der Zulassungsbehörde in Kanada geht es um die Zulassung von Oral-lyn dem Insulin-Spray von GNBT, wobei das Insulin über die Mundschleimhaut aufgenommen wird.

Es wird wohl darüber gesprochen, ob die bisherigen Daten ausreichen um eine Zulasung zu beantragen - ist unwahrscheinlich - und welche Tests noch notwendig sind um eine Zulassung zu beantragen.
Wenn die noch notwendigen Tests nicht allzu Umfangreich sein müssen und nicht allzu lange dauern, wäre das sensationell für GNBT.
Oral-lyn hätte in Kanada einen guten Markt und die Zulassung in anderen Ländern wäre ziemlich sicher.
Wenn ersichtlich ist, dass Oral-lyn in Kanada in absehbarer Zukunft zugelassen wird, würde das einen kräftigen Kursschub bewirken.

therman

[Xepher]

ää...also ich weis nicht....ob dieses GAP noch geschlossen wird.
wir werden ja sehen
auf jeden fall ist GENEREX heiß...cool...und voller phantasie.
ich bin long....

schönen abend noch
salut xepher

[therman]

[posting]20.330.095 von Xepher am 22.02.06 18:12:15[/posting]Ob das Gap geschlossen wird, muß man abwarten,
darauf spekulieren würde ich nicht.

Ich bleibe investiert.

Ein Rücksetzer, wenn er kommt, wäre eine gute Kaufgelegenheit.

therman

[Xepher]

so is es therman

amen brother

[jojobada]

Guten Morgen@all,

mal schaun wie es weiter geht. Es ist offensichtlich, dass sich noch einige in USA eindecken müssen.

Abwarten. Gruß jojo

[tippse]

weiß hier eigentlich jemand, was der unterschied zwischen "exubera" von pfizer und "orla-lyn" von generex ist

26.01.2006 18:30
Pfizer: EU lässt Exubera für Typ-1- und Typ-2-Diabetes zu
NEW YORK (Dow Jones)--Die Pfizer Inc, New York, hat die lange erwartete EU-Zulassung für ihr Diabetes-Medikament "Exubera" erhalten. Die EU-Kommission habe eine Marktzulassung für die Behandlung von Diabetes Typ 1 und Typ 2 erteilt, teilte der US-Pharmakonzern am Donnerstagabend mit. Bei Exubera handelt es sich um die erste inhalierbare Form des Humaninsulins. Üblicherweise müssen Diabetiker das vor mehr als 80 Jahren entdeckte Insulin spritzen.

Exubera hat Blockbuster-Potenzial. Pfizer hat es gemeinsam mit Aventis entwickelt, doch kam es nach der Aventis-Übernahme durch Sanofi Synthelabo zu einem Rechtsstreit der Partner. Vor knapp zwei Wochen beendeten ihn beide Seiten mit einem Vergleich. Für 1,3 Mrd USD kaufte der US-Konzern dem französischen Unternehmen alle Rechte ab und übernimmt dabei auch die Exubera-Produktionsstätte im Industriepark Frankfurt-Höchst.

Wegen befürchteter Nebenwirkungen auf die Lunge im Langzeitgebrauch hat sich die Zulassung des Mittels um Jahre verzögert. In den USA wartet Pfizer noch auf die Genehmigung der FDA. Der US-Gesundheitsbehörde liegt seit September allerdings ein positives Votum von einem Expertengremium vor.

-Von Olaf Ridder, Dow Jones Newswires; +49 (0)69 - 29725 111,

[e-mail]

http://www.faz.net/d/invest/meldung.aspx?id=18699889&news=un…

*********************************************************

29.01.2006 14:19
FDA genehmigt Diabetespräparat Exubera von Pfizer
WASHINGTON (Dow Jones)--Die Food and Drug Administration hat das erste inhalierbare Insulin für die Behandlung von erwachsenen Diabetikern zugelassen. Das Medikament "Exubera" von der Pfizer Inc, New York, ist damit das erste nadelfreie System zur Kontrolle des Blutzuckerspiegels. Wie die FDA am Freitagabend mitteilte, wurde Exubera für beide Diabetestypen zugelassen.

Laut Pfizer soll das Medikament Mitte des Jahres auf den Markt kommen. Die europäische Gesundheitsbehörde hatte das Mittel bereits am Donnerstag zugelassen. Analysten rechnen damit, dass Exubera Blockbuster-Status erreichen kann, mit einem Umsatz von 1 Mrd USD jährlich und mehr. Zu Beginn des Monats hatte der US-Pharmakonzern Sanofi-Aventis 1,3 Mrd USD für die weltweiten Rechte an Exubera gezahlt.

- Von Jennifer Corbett Dooren, Dow Jones Newswires;

[phone], [e-mail]

DJG/DJN/nas


http://www.faz.net/d/invest/meldung.aspx?id=18829517&news=un…

[therman]

[posting]20.347.973 von tippse am 23.02.06 18:00:32[/posting]Exubera wird inhaliert und in der Lunge aufgenommen.
Deshalb auch:Wegen befürchteter Nebenwirkungen auf die Lunge im Langzeitgebrauch hat sich die Zulassung des Mittels um Jahre verzögert.

Oral-Lyn von GNBT wird in den Mund gesprüht und von der Mundschleimhaut aufgenommen.

Ich sehe deshalb einen klaren Vorteil für Oral-Lyn vom Produkt her.
Der Nachtteil für Oral-Lyn ist, dass es in den USA später auf den Markt kommen wird, und dass GNBT eine kleine Firma ist, die nicht soviel Schmiergeld bezahlen kann.

therman

[sebcoe]

[posting]20.352.773 von therman am 23.02.06 22:23:53[/posting]möglicherweise gesellt sich im rahmen einer vertriebskooperation ja ein marktmacht besitzendes unternehmen hinzu, das über meinungsbildner und multiplikatoren äh ich meine lobbyisten, die auch gerne tief in die tasche greifen, verfügt. phantasie ist jede menge vorhanden...
glück auf

[therman]

[posting]20.353.896 von sebcoe am 24.02.06 00:17:42[/posting]das hoffe ich auch sebcoe

Phantasie und Potential sind wirklich gigantisch.

therman

[HoTsTePPa.]

Wie in den letzten 3 Tagen wieder massiver Kaufdruck. Wird weiterhochgehen .

Buy:Sell 87:15

[frank55]

Heute noch 1,80 Euro?

[Xepher]

die 2$ fällt

[frank55]

Im Aktionär Kursziel 2,50 Euro

[sebcoe]

rt 2,17 kann mein Glück heute aufgestockt zu haben kaum fassen

[Fasu]

Und warum der Ausbruch und das am Freitag ????
Gibbett NEWS ???????????????????????
Und weg....................

[HoTsTePPa.]

Weil alle Zocker draussen sind. Schön ruhig hier und Generex macht heut lockere 15 %. Ist halt auch was dahinter...

2,20 $

[sebcoe]

[posting]20.367.987 von HoTsTePPa. am 24.02.06 18:25:55[/posting]2,29 Rt we are skyrocketing
der Kurs wird ohnehin alleine an der nasdaq gemacht, der aktionär ist unerheblich

[talla3xlc]

hey was meint ihr wie hoch werden die maximal gehen

hoffe das liegt jetzt nur grade an der aktuellen vogelgrippe geschichte...


gruss berti

[jojobada]

Sie kamen wie aus dem Nichts und kauften und kaufen immer noch!

jojobada

[HoTsTePPa.]

Wie aus dem Nichts ist nicht richtig. Wer die letzten 5 Tage das Orderbuch betrachtet hat, hat gesehen, das ein enormer Kaufdruck herrschte. Der sich heute entlud.

Allerdings hab ich höchstens 2,1 erwartet.

[sebcoe]

das Betrachten des Charts von beispielsweise BCRX veranschaulicht die enormen Chancen und sollte helfen ggf. aufkommende Gedanken an Gewinnmitnahmen im Keim zu ersticken. Nicht nur im Chart ist noch sehr viel Luft nach oben. Auch die fundamental gute Aufstellung des Unternehmens sowie die glänzenden Perspektiven sind noch längst nicht eingepreist.

[therman]

http://biz.yahoo.com/iw/060227/0111153.html


Generex Biotechnology to Present Pandemic Influenza

Vaccine Program at Bird Flu Summit in Washington, D.C.
Monday February 27, 9:00 am ET


Synthetic Peptide Vaccine for Avian Influenza Provides H5N1 Specific T Helper Stimulation


TORONTO--(MARKET WIRE)--Feb 27, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that Dr. Douglas Powell, Ph.D., Director of Immunobiology of Antigen Express, Inc., the Company`s wholly owned subsidiary, will make a presentation at an international conference on the Antigen Express program for the development of a novel synthetic peptide vaccine designed to protect against the potentially pandemic avian influenza virus.

[sebcoe]

2 Katalysatoren, die den Kurs momentan treiben; ein überaus erfreuliches Volumen die letzten Tage; das Unternehmen scheint in den Focus institutioneller Investoren gerückt zu sein.

[sebcoe]

2 Katalysatoren, die den Kurs momentan treiben. sehr erfreuliches Volumen die letzten tage. das unternehmen scheint in den focus institutioneller investoren geraten zu sein.

[therman]

Habe heute ein Drittel meiner GNBT Aktien verkauft zu 2,6 Dollar.
Bei GNBT dürfte das weitere Potential kurzfristig begrenzt sein.

Habe bei NGEN zugekauft, rechne hier ebenso wie bei BIOM und GNTA und INSM mit einem Schub nach oben.

therman

[therman]

Habe ein weiteres Drittel bei 2,49 $ verkauft.

Konsolidierung bahnt sich an, meiner Meinung nach.

Möchte billiger wieder zurückkaufen.

therman

[sebcoe]

[posting]20.407.051 von therman am 27.02.06 17:51:01[/posting]Konsolidierung ist gesund und der Nährboden für steigende Notierungen; glaube fest daran, dass wir in einer Woche höher stehen als heute.
vg
glück auf

[Eymen]

Ich habe nach gekauft.

[therman]

[posting]20.407.528 von sebcoe am 27.02.06 18:12:22[/posting]Glauben hilft an der Börse nicht weiter.

schon möglich, dass der Kurs in einer Woche höher steht.

Die Gefahr einer stärkeren Korrektur zeigt sich in der nachlassenden Dynamik des Kursanstiegs.

Warten wirs ab, ob ich wieder günstiger nachkaufen kann.

therman

[therman]

[posting]20.407.669 von Eymen am 27.02.06 18:19:23[/posting]Der steile Aufwärtstrendkanal auf Stundenbasis ist gebrochen.

Kurs zur zeit: 2,35 Dollar.

therman

[therman]

Hier ein link für den realtimekurs:

http://datasvr.tradearca.com/arcadataserver/JArcaBook.php?Sy…

therman

[elfederiQo]

kleine korrektur vorm 1. März, das passt ins Bild....aber ich denke, unter den Bereich von ca. 1,70 - 1,85 USD sollten wir nicht fallen.

wait and see

[sebcoe]

[posting]20.407.874 von therman am 27.02.06 18:29:04[/posting]ich maße mir nicht an mich als Wissenden bzw. Sehenden zu bezeichnen; die Rolle des Chartgurus, der Kurse punktgenau vorauszusehen vermag, ist hier ja bereits an den roten Schuh vergeben.
wenn ich schreibe glaube, dann meine ich, dass ich vermute, nutmaße, spekuliere, mir vorstelle oder was auch immer. selbstredend ist der wunsch der vater des gedanken. 2,6 war sicher kurzfristig kein schlechter ausstiegszeitpunkt. ich für meinen teil bin bereit, konsolidierungen und kursrückgänge auszusitzen. von daher denke ich, dass wir unterschiedliche strategien fahren.

[therman]

Wir haben unterschiedliche Strategien, das ist richtig.

Ich versuche kurzfristige Schwankungen auszunutzen, und versuche vor allem, größere Verluste zu vermeiden.

Ich rechne, dass es zu einem Rückgang bis ca. 2,2 bis 2 Dollar kommt, vielleicht auch mehr.
Das hängt auch vom morgigen Treffen mit der Zulassungsbehörde ab.
Möglicherweise sehen wir morgen sogar noch einmal höhere kurse als heute.

therman

[sebcoe]

[posting]20.408.606 von therman am 27.02.06 19:06:34[/posting]momentan ist die 2,45 hart umkämpft; werden die 2,50 zurückerobert, dann wäre das m.E. ein zeichen technischer stärke, das zudem zu neuen tageshöchstkursen führen würde.
besser sekt saufen und poppen, als abwarten und tee trinken

[therman]

[posting]20.409.072 von sebcoe am 27.02.06 19:31:40[/posting]"besser sekt saufen und poppen, als abwarten und tee trinken"

da simme ich Dir voll zu

therman

[sebcoe]

morgen präsentiert GNBT auf der Vogelgrippenkonferenz, übermorgen dann das Treffen mit der kanadischen Zulassungsbehörde und jetzt tripple bottom?! bei 2,40.
in der letzten Handelsstunde, wenn die profis in erscheinung treten, sowie morgen fliegt hier die kuh.

es lebe die liebe, der leichtsinn, der suff, der uneheliche beischlaf, der papst und der puff

[sebcoe]

[posting]20.410.502 von sebcoe am 27.02.06 20:36:01[/posting]rt 2,43 dreifachboden kristalisiert sich langsam heraus from here up up we go.

[mfierke]

huuuuuu, ein Board mit vielen fremdwörtern

[sebcoe]

[posting]20.406.786 von therman am 27.02.06 17:38:56[/posting]beim verkauf haste ein glückliches oder sollte ich goldenes, nein, ich denke das wäre voreilig händchen bewiesen oder besser gesagt den richtigen riecher gehabt.
vermag mir nicht vorzustellen, dass wir die kursspitze angesichts der anstehenden ereignisse bereits heute gesehen haben.
Man kann nicht mit allen frauen auf dieser welt schlafen, aber man sollte es zumindest versuchen(George Simeon)

[therman]

[posting]20.412.074 von sebcoe am 27.02.06 22:07:54[/posting]Ich gehe davon aus, dass wir heute eine Kursspitze gesehen haben, und deutlich tiefere Kurse sehen werden.

Für diese Annahme spricht das aussergewöhnliche Volumen von 37,820,757 Aktien, die gehandelt wurden, und die heutige Kerze, ein BEARISH LONG LEGGED DOJI - dieses Verkaufssignal bedarf allerdings der bestätigung.

In der Vergangenheit von GNBT gab es bei derartigen Volumenspitzen in Verbindung mit Höchstkursen und überhitztem RSI jedesmal eine deutliche Korrektur.

Schaun mr mal ob´s diesmal auch so wird.

Mir wäre es nicht unrecht, wenn der Kurs nochmal bis 1,4 Dollar runtergeht, dies ist durchaus möglich.

Trotzdem bleibe ich mit dem restlichen Drittel meiner Aktien investiert. Die restlichen zwei Drittel, das sind 6000 Aktien werde ich günstiger wieder zurückkaufen.
Das heißt es werden dann mehr als 6000 sein, denn ich werde den Betrag investieren, den ich beim jetzigen Verkauf erhalten habe.

therman

[sebcoe]

[posting]20.412.489 von therman am 27.02.06 22:31:59[/posting]Doji hin oder her...ich denke, dass dermaßen viel begründete phantasie vorhanden ist, dass wir ende der woche die 3 von oben sehen. solltest du recht behalten, mdann wäre dein timing optimal gewesen und ich würde ehrfurchtsvoll meinen hut ziehen und dir den dir dann gebührenden respekt zollen.

welche anderen unternehmen hälst du(aus welchen gründen?)für aussichtsreich?

[therman]

[posting]20.412.773 von sebcoe am 27.02.06 22:54:43[/posting]Langfristig sehe ich sehr viel potential für GNBT, keine Frage.

Einige Andere Aktien die ich zur Zeit halte sind:

AGEN, Genaera, BIOMira, GeNTA, Insmed, Medarex, Vical, Vion.

All diese Aktien halte ich auf Grund ihrer Technologie, Produkte oder ProduktKandidaten für langfristig sehr aussichtsreich, und alle sind chartmäßig in einer "bullishen" Phase.
Für Details bitte in meinen threads zu diesen Aktien nachschauen.

Gut Nacht, muss morgen früh raus.

therman

[sebcoe]

der kurs hat sich in der nachbörse stand momentan bei einem volumen von 200000 stück von anfangs 2,31 auf 2,43 erholt. schwächt das die doji theorie ggf. ab?

[HoTsTePPa.]

[posting]20.413.760 von sebcoe am 28.02.06 00:40:35[/posting]Ich würd sagen, das ist kein Doji.
Das ist der Bulle von Tölz!!

[mfierke]

BOSTON (Dow Jones) -- Anteile von Generex Biotechnologie und BioCryst pharmazeutische Produkte beide stark gesprungen am Montag, Angebot vor ihren zeitlich geplanten Darstellungen bei einem Vogel-Grippe Gipfeltreffen. Beide Firmen entwickeln die Drogen, die Vogelgrippe bekämpfend angestrebt werden. Generex und BioCryst sind schiefergedeckt, Dienstag Darstellungen am zweitägigen Vogel-Grippe-Gipfel zu bilden, eine Konferenz auf der Drohung eine internationale pandemic kennzeichnenöffentlichkeit und Privatsektor der Lautsprecher, die Montag in Washington anfingen. Anteile von Generex (GNBT) schossen herauf 12% bis $2.48, während BioCryst (BCRX) 8% bis $21.35 am Mittag sammelte. Nach Ansicht des neuen Konferenzorganisators Fängt ` Web site, der Direktor des Programms peramivir BioCrysts bildet einen Darstellung Dienstag Nachmittag auf. Die Firma hat peramivir, ein Antiviren, als mögliche Behandlung für Vogelgrippe entwickelt. Ebenso wird ein Repräsentant Impfstoffmaßeinheit des Antigens Generexs von der ausdrücklichen an einem Verkleidung Diskussion Dienstag Morgen auf den Gefahr-Nutzen Ausgaben teilnehmen, die mit einem pandemic, entsprechend dem neuen verbunden sind, auffängt Web site. Generex hat einen Vogel-Grippe vaccine Anwärter entwickelt, der auf seiner ausdrücklichen Technologie des Antigens basiert. Andere biotechs engagierten sich in der auch gesammelten Vogel-Grippe Forschung, einschließlich Alnylam pharmazeutische Produkte (ALNY), Vical (VICL), Novavax (NVAX), Hemispherx (HEB), pharmazeutisches Nastech (NSTK), Avant Immunotherapeutics (AVAN) und Avi Biopharma (AVII). Bei der Konferenz auch sich darstellen ist medizinische Produkte und Vorrichtung Firmen Aethelon Medical und Pall Corp. San Diego-gründete Aethlon (AEMD), dessen Aussehen für neueren Montag festgelegt wird, hat entwickelt eine Vorrichtung, die das Hemopurifier genannt wurde. Die Vorrichtung, die mit Dialysemaschinen benutzt werden kann, soll die Menge eines Virus im Körper, entsprechend Web site der Firma verringern. Hülle (PLL) bildet Filtrationsysteme, die in der vaccine Produktion auch benutzt werden können. Hülle, auf Hahn während eines Dienstag Nachmittages. Die Osthügel, N.Y., gründeten die Marken der Firma auch, die Entlüfter atmen, die benutzt werden können, um die Verbreitung solcher Viren wie SARS und verschiedene Belastungen der Grippe zu entmutigen.

[sinfonie]

Guten Morgen, dies zur Erinnerung:
http://www.generex.com/products/oral-lyn/
Schönen Tag noch, morgen wird es spannend

[sinfonie]

Nachbörslich 2,45$ = + 2,94 %

[sebcoe]

GNBT wird heute auf jeden Fall Presse und aufmerksamkeit bekommen. das handelsvolumen von 28 millionen stück war schwindelerregend. gar nicht auszudenken wenn in der momentan explosiven gemengelage z.b. eine kaufempfehlung ins haus flattern würde...

[mfierke]

Flaggschiffprodukt Generexs, Generex Mündlich-lyn?, ist ein Mundinsulinspray für die Behandlung von Diabetes. Generex Mündlich-lyn? ist eine flüssige Formulierung des regelmäßigen menschlichen Insulins, die an den bukkalen Mucosa über das RapidMist geliefert wird? Vorrichtung, in der Absorption auf die Öffnung ohne Eintragung in die Lungen begrenzt wird. Das reiche vascularity des bukkalen Mucosa läßt viel schnellere Absorption des Insulins und eine kürzere Gesamtdauer der Tätigkeit zu, die Generex Mündlich-lyn bildet? ein ideales prandial Insulin, wie es sofort vor Mahlzeiten mit weniger Aussicht von hypoglycemia bequem ausgeübt werden kann. Generex Mündlich-lyn? kann als vorbeugendes pharmakologisches Mittel von den Leuten mit Vordiabetes zu verwendet werden verzögert den Angriff von Diabetes und durch Patienten mit Diabetes type-2 zu verzögert den Angriff der Insulinabhängigkeit und die Komplikationen, die mit Diabetes verbunden sind. Generex Mündlich-lyn? wird erwartet, zu eine enorme Verbesserung in der Lebensqualität, mit der Beseitigung der Schmerz und einer bedeutenden Zunahme der Bequemlichkeit zu führen. Dieses ergibt verbesserte Befolgung einer relativen Abnahme an den Komplikationen und einer bedeutenden Verringerung der enormen Kosten, die mit dem Behandeln sie verbunden sind

[therman]

[posting]20.413.760 von sebcoe am 28.02.06 00:40:35[/posting]Letzter nachbörslicher Kurs war 2,38Dollar, also unverändert.

Es ist übrigens kein astreiner Doji, dazu müssten die Schatten absolut gleich lang sein.
Die Kerze zeigt den Kampf zwischen Bullen und Bären.

Mal sehen wer heute die Richtung bestimmt, Bullen oder Bären.

Gestern wurden 37,820,757 Akien an der Nasdaq gehandelt, dazu kommen nochmal über 20 Millionen ausserbörslich,
das macht zusammen ca. 60 Mill., und gerade mal 60Mill. Aktien sind überhaupt im Umlauf.

Große Markteilnehmer haben wahrscheinlich mit Computergesteuerten Kauf und Verkaufsprogrammen das Marktgeschehen gesteuert.

therman

[jojobada]

Gewinne mitnehmen, Korrektur abwarten!

jojo

[elfederiQo]

schönen Gruß an die Übersetzungsautomaten

ist wohl besser es gleich auf Englisch zu lassen, oder selbst zu übersetzen, denn "bukkalen Mucosa über das RapidMist geliefert" klingt schon sehr lustig

[sebcoe]

ich sehe genauso wie sinfonie einen nachbörslichen kurs von 2,43.möchte mich aber nicht darüber streiten, ist um 14:00 ohnehin makulatur.
es ist zutreffend, dass an gewinnmitnahmen noch nie jemand gestorben ist.lieber den spatz in der hand, als die taube auf dem dach.
dessen ungeachtet glaube ich an höhere kurse und bin nicht bereit meine papierchen zu diesem kurs zu verscherbeln.
ich halte die aktie trotz des jüngsten anstiegs für günstig.
die zeit wird zeigen wer richtig liegt.

[sebcoe]

[posting]20.416.307 von sebcoe am 28.02.06 09:18:24[/posting]2,43 war ein schreibfehler, richtig ist 2,45
kurs in ffm damit 10 cent unter paari, die mehrheit der marktteilnehmer scheint eure einschätzung zu teilen

[Eymen]

Was ich will ist ein Gute Nachricht
Den Rest erledigt der Markt von selbst
chat analise hin und her

[sebcoe]

Vorbörse 2,50

[tobijack]

na das sieht doch gut aus

[Eymen]

Da sind aber alle sprachlos

[therman]

[posting]20.416.307 von sebcoe am 28.02.06 09:18:24[/posting]Ich weiss nicht, wo ihr Info über den letzten nachbörslichen Kurs her habt.
Wenn man bei yahoo nachschaut, stimmt es meistens nicht.

Hier ein link der korrekte kurse liefert.

http://bigcharts.marketwatch.com/javachart/javachart.asp?sym…


Bis jetzt sieht es so aus, als ob deas gestrige verkaufsignal bestätigt wird, dafür muss der Schlusskurs heute jedoch unter dem Schlusskurs von gestern liegen, dann liegt ein bestätigtes Verkaufsignal vor.

therman

[therman]

Die andere Variante ist, dass bei 2,3 Dollar ein Doppelboden gebildet wird und es weiter aufwärts geht.

therman

[therman]

2 Aktien bei denen es heute und vermutlich die nächsten Tage weitr hochgeht sind zum Beispiel:

GeNTA und INSM.

Da sollte man jetzt dabei sein.

therman

[mfierke]

das wird heute nichts, habe meine heute morgen verkauft, wir kommen wieder billiger rein

[therman]

Die Ausübung der Warrants, siehe Meldung drückt auf den Kurs.

http://biz.yahoo.com/iw/060228/0111377.html

Generex Biotechnology Receives $11 Million From Warrant Exercises
Tuesday February 28, 8:58 am ET


Company Now Has in Excess of $31 Million in Cash-on-Hand


TORONTO--(MARKET WIRE)--Feb 28, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that it has received an aggregate of $11 million as a result of the exercise by existing Company investors of previously issued warrants. The receipt of these funds has put the Company`s cash-on-hand at more than $31 million, its strongest cash position in more than four years.

[mfierke]

dann bleiben wir mal an de Seitenlienie stehen

[therman]

Die Ausübung der Warrants hat jedoch auch einen positiven Effekt, nämlich, dass GNBT jetzt 31 Mill. Dollar in der Kasse hat, und damit die weiteren Testreihen bezahlen kann, um Oral-lyn in den wichtigen Märketen zu platzieren.

Das heißt, die langfristigen Aussichten haben sich damit weiter verbessert, aber es kann weiterhin sehr volatil bleiben wie im Fahrstuhl auf und ab.

therman

[elfederiQo]

[posting]20.425.344 von therman am 28.02.06 16:24:46[/posting]sehe ich auch so....bissl konsolidieren, dann ein wenig aufstocken, es gilt, scharf zu beobachten...

[mfierke]

[posting]20.426.620 von elfederiQo am 28.02.06 17:15:09[/posting]ein bisschen ist gut 2,25 ist 1,90 € das hätte mir mit meien Stücke schon sehr weh getan

[therman]

Die von mir erwartete Korrektur ist voll im Gange.

Unterstützungen befinden sich bei: 2,08 - 1,8 - 1,64 - 1,33 - Dollar.

Ich kaufe dann zurück, wenn sich ein Kaufsignal andeutet.

therman

[mfierke]

[posting]20.429.155 von therman am 28.02.06 18:48:19[/posting]kannst du mir über BM einen funk geben, da ich nicht immer am PC bin. danke für die Bemühungen, möchte auch wieder rein gruß mfierke

[mfierke]

[posting]20.429.155 von therman am 28.02.06 18:48:19[/posting]puhhhhhhhhhhh wir sind ja unter 2,09

[Xepher]

bin rein zu 1,68 €

[mfierke]

[posting]20.429.487 von Xepher am 28.02.06 19:01:19[/posting]gratuliere ich erst zu 1,80

[sebcoe]

[posting]20.424.628 von therman am 28.02.06 15:56:26[/posting]archipelago, inet und etrade haben den in rede stehenden kurs übereinstimmend so angegeben. schnee von gestern

[sebcoe]

volume preceeds price which preceeds news.

p.s. wer keine englischkenntnisse besitzt, sollte tunlichst nicht in ein kanadisches biotechunternehmen investieren, sondern sich schnurstracks in die spielbank begeben.
oder etwas für seine allgemeinbildung tun und einen vhskurs belegen.

[mfierke]

[posting]20.434.145 von sebcoe am 28.02.06 22:19:20[/posting]etwas für seine allgemeinbildung tun und einen vhskurs belegen . [/B]
man sollte nicht mit Steinen schmeißen, wenn man im Glashaus sitzt. Ein Rechtschreibekurs wäre bei Dir auch angebracht

[sebcoe]

[posting]20.435.604 von mfierke am 01.03.06 06:28:08[/posting]weil ich bewußt auf groß- und kleinschreibung verzichte? pah. ein klassisches eigentor, das du da geschossen hast.richtig lautet das sprichwort nämlich:wer im glashaus sitzt, sollte nicht mit steinen werfen.
menschen, die steine schmeißen, haben womöglich eine vergangenheit als apostraßenkämpfer, die sie nostalgisch verklären.on y soit qui mal y pense.für dich auf deutsch:ein schelm wer böses denkt.

[Eymen]

Können wir uns auf GNTB konzertierten bitteKönnen wir uns auf GNTB konzertierten bitte
Heute sollen NEWS kommen was mein Ihr.!!

[sebcoe]

über die präsentation bei der vogelgrippelonferenz habe ich nichts finden können; eine verlautbarung über das trffen mit den kanad. behörden erwarte ich frühestens morgen

[frank55]

Um 15.30 schiesst sie bestimmt über 2 Euro

[sebcoe]

habe heute teilverkauf getätigt. habe muffensausen bekommen.

[sebcoe]

habe heute teilverkauf vorgenommen; habe muffensausen bekommen, position war zu groß

[sebcoe]

[posting]20.442.352 von frank55 am 01.03.06 14:09:24[/posting]habe heute teilverkauf getätigt. die position war so groß, dass ich muffensausen hatte.

[sebcoe]

[posting]20.424.628 von therman am 28.02.06 15:56:26[/posting]Hut ab, Du hast ein feines gespür bewiesen und die (kurzfristige?) kursspitze nahezu genau getroffen. ich verneige mich anerkennend.

[therman]

Nachbörslicher Kursanstieg bis 2,31 letzter Kurs.

Mal sehen wie es heute weiter geht.

Link zu Offiziellen nachbörslichen kursen:

http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx…

therman

[sebcoe]

kann mich nicht entsinnen bei gnbt vorbörslich ein so prallgefüllten ask gesehen zu haben hmmm

[sebcoe]

unter www.generex.com gibt es eine presseerklärung zu oral lyn

[hri]

grad news, bin noch haarscharf reingekommen !

[sebcoe]

2,38 und heftiges volumen; markt scheints zu honorieren

[hri]

Generex Biotechnology Completes Positive Pre-NDS Meeting With Health Canada for Generex Oral-lyn(TM)
Friday March 3, 8:45 am ET


Company Now Has Clear Roadmap to NDS


TORONTO--(MARKET WIRE)--Mar 3, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that on March 1, 2006 the Company concluded a positive Pre-New Drug Submission (NDS) meeting with the Regulatory Affairs Division of the Biologics and Genetic Therapeutics Directorate of Health Canada in respect of Generex Oral-lyn(TM), the Company`s proprietary oral insulin spray product for the treatment of diabetes.

[hri]

RT 2,39/2,40 last 2,40

[hri]

die wär schon bei 2,50 wenn der ami-fut. nich so negativ wär

[HoTsTePPa.]

Gestern ging die doch auch vorbörslich soi hoch um wieder runter zu gehen.

[hri]

[posting]20.487.925 von HoTsTePPa. am 03.03.06 15:13:57[/posting]is halt sehr volatil

[HoTsTePPa.]

Ich depp hab kurz vor dem Anstieg in Deutschland geschmissen. Weil das Orderbuch viel mehr Verkäufer hatte.

Shit happens.

[HoTsTePPa.]

wollte aber auch liber in US rein und die deutschen Shares loswerden.

[hri]

[posting]20.488.162 von HoTsTePPa. am 03.03.06 15:21:05[/posting]na kommt wieder runter 2,31/232 der übliche push nach der meldung eben

[hri]

bin schon wieder raus, nice gain, 400 ocken in 20 minuten, leiter bekam ich nur 4000 stück, ging so schnell !

[HoTsTePPa.]

[posting]20.488.383 von hri am 03.03.06 15:27:21[/posting]In Deutschland zu 1,89?

[hri]

1,99 obwohl wenn der future drehen sollte überleg ich mirs nochmal rein zu gehen

[hri]

2,27 wie ichs mir dachte, dem neg. fut. kann sie auch nicht widerstehen

[sebcoe]

wie ein jojo auf und ab; mal sehen, was passiert, wenn die profis ins geschehen eingreifen

[hri]

na nach der INTC-umsatzwarnung seh ich für heut schwarz, da werden die amis sich auf freitag wohl so richtig ausko.... warten wir die erholung ab

[sebcoe]

mal schaun, ob der dicke askblock bei 2,40 aufgesogen werden wird...

[hri]

der markt ist zu unstätig heute und der vix steigt auch

hab nach wie vor kein vertrauen heute in den markt, da auf 60 min. chart (QQQQ) immer noch VK

[hri]

und in usa nen short zu machen ist mir auch zu heiß

[Eymen]

aha die Zocker sind auch da

[sebcoe]

scheint nur ein kurzes gastspiel gewesen zu seinsehr enge handelsspanne heute...einen sell on good news hat es auch nicht gegeben hmmm...

[mike38]

Schöner Tag heute wieder. 2006 wird das Jahr der Biotecs!! Schweinepest, Vogelgrippe wer Diesjahr die richtigen Aktien im Depot hat wird reich. Schönes Wochnende. PS. Generex steigt schön weiter im Amiland!!!

[DR.DIAMOND]

Diese Meldung war den Investoren nur ein Plus von
10 Cents wert.Ich verstehle das nicht
Vielleicht klopft ja einmal ein Pharma-Multi an die Tür
von Generex.
Generex to File for Canada Insulin OK
Friday March 3, 9:58 am ET
Generex to File for Canadian Approval of Oral Insulin Spray Following Meeting


NEW YORK (AP) -- Drug developer Generex Biotechnology Corp. said Friday that it has a clear idea on how to go about getting Canadian marketing approval for its oral insulin spray after talking to regulators.
The company said that it recently met with the regulatory affairs division of Health Canada`s biologics directorate to discuss strategies on how to submit its marketing application for its Oral-lyn oral insulin spray for the treatment of diabetes.

Generex expects that the filing for Canadian approval will help it with filings with U.S. and European regulators.

Shares of Generex rose 8 cents, or 3.6 percent, to $2.30 in morning trading on the Nasdaq. Over the past 52 weeks, shares have climbed from a low of 51 cents last April to a high of $2.75 on Feb. 27, and have more than doubled in value since the start of the year.

[Onkelbaer]

[posting]20.502.260 von DR.DIAMOND am 04.03.06 11:02:15[/posting]Hi Dr. Diamond,

Ja wieso sollte der Markt auch anders darauf reagieren? Ist doch ne total inhaltlose Nachricht, genauso als wenn ich sagen wuerde "Ich will eines Tages Millionaer werden!" Diese Absichtserklaerung enthaelt dabei so gut wie keine Info, denn wer an der Boerse will nicht mit seinen Investments reich werden? Auf der anderen Seite allerdings fehlen wichtige Angaben, wie lange ich z.B. plane dafuer zu brauchen, und wie ich das anstellen will.

Diese Nachricht ist genauso eine indifferente Absichtserklaerung, denn das GNBT vor hat Oral-lyn auf den kanadischen Markt zu bringen, war doch schon laenger bekannt und das sie sich mit der kanadischen Gesundheits-Behoerde treffen wollte auch. Wirklich interessant waere zumindest fuer mich gewesen zu erfahren, was da genau besprochen wurde, dh. welche Massnahmen noch ergriffen werden muessen, bis das Produkt die Freigabe fuer den kanandischen Markt erhaelt. Ausserdem wuerde mich interessieren, wie lange es voraussichtlich dauern wird diese Auflagen zu erfuellen, dh. auch wie lange es dauert bis GNBT auch in Kanada Einnahmen aus Oral-lyn generieren kann. Denn es kann doch gut sein, dass auch fuer Kanada, aehnlich wie in den USA, noch weitere klinische Tests erforderlich sind, die noch ne ganze Menge Zeit brauchen und viel Geld kosten. All diese und noch viele Fragen mehr bleiben einfach offen. Waeren diese beantwortet worden, dann haette der Effekt auf den Aktienkurs auch wesentlich groesser ausgesehen, nach OBEN falls die dargestellten Fakten positiv sind, dh. kurze Zeiten und geringe Kosten, und nach UNTEN wenn dem nicht so waere! Es gibt viele Investoren an der Boerse, die es ueberhaupt nicht moegen im Unklaren gelassen zu werden, und genau das tut diese Presse-Mitteilung. Sie bestaetigt Fakten, die schon bekannt waren, aber laesst jede Menge Fragen offen. Aus diesem Grund lassen viele potentielle Anleger einfach die Finger von der Aktie! So einfach ist das!


Ich bin zur Zeit allerdings (noch) froh, dass das der Fall ist, weil zur Zeit mein Kohle noch in anderen Investments steckt, und ich da noch auf die richtige Ausstiegsgelegenheit warte, um dann auf GNBT "umzuschichten". Also fuer mich darf daher die Konsolidierung gerne noch ein wenig so weiter gehen, bis auch ich an Board bin. Denn auf Lange Sicht, dh. fuer die naechsten 1-2 Jahre, sehe ich auch, wie die Meisten hier im Board, gigantisches Kurspotential fuer diese Aktie, insbesondere, um nur einen Grund zu nennen, weil dieser Titel schon jetzt ein NASDAQ Wert ist und nicht an der OTC gehandelt wird, wie so viele vergleichbare Aktien.

In diesem Sinne ein schoenes WE fuer allen Beteiligten.

Greets Onkelbaer

[therman]

Stimme dir zu Onkelbaer,

in der Presseerklärung fehlt jeglicher Hinweis, wann der Antrag für die Zulassung von Oral-lyn erfolgen wird.

Aber es ist erkennbar, das GNBT sicher ist, dass der Zulassungsantrag erfolgreich sein wird.
Ich denke folgender Text aus der Erklärung mach das deutlch:"The informed and vigorous engagement of the Health Canada representatives in our meeting was most gratifying," said Anna Gluskin, Generex President & Chief Executive Officer. "We now have clearly defined objectives in a roadmap to a successful New Drug Submission for Generex Oral-lyn(TM) and we will move expeditiously to achieve those objectives and prepare the NDS." The NDS will include all clinical data, bio-statistical analyses, sample batches, chemistry, manufacturing and controls (CMC), production schedules, and medical device licensing."
The Company expects that the NDS documentary package, together with the April, 2005 approval of Generex Oral-lyn(TM) by the Ecuadorian Ministry of Public Health, will advance similar filings for regulatory approvals with the United States Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA).

Es geht jedoch nicht daraus hervor, ob neue klinische Versuchsreihen notwendig sind, und wie lange diese dauern könnten.

Warum macht GNBT dies:

2 mögliche Szenarien:

1. Es dauert noch relativ lange, bis die Zulassung beantragt werden kann und GNBT will dies jetzt nicht sagen, um den Aktienkurs zu stützen.

2. Der Zulassungsantrag kann relativ zügig eingereicht werden weil alle Daten schon vorhanden sind und sie müssen nur noch entsprechend ausgewertet und dargestellt werden.
GNBT gibt dies jedoch noch nicht bekannt, weil irgend jemand noch günstig Aktien einsammeln möchte, vielleicht ein Partner, mit dem sie schon im Gespräch sind. Sobald bekannt würde, dass der Antrag zügig eingereicht wird, also in den nächsten Wochen oder Monaten, würde der Aktienpreis in die Höhe schießen und einsammeln auf günstigem Niveau wäre nicht mehr möglich.

diese 2 Szenarien sind reine Spekulation.

"We now have clearly defined objectives in a roadmap to a successful New Drug Submission for Generex Oral-lyn(TM) and we will move expeditiously to achieve those objectives and prepare the NDS."
Freie sinngemässe Übersetzung vom mir:
"Wir haben jetzt klar definierte Anhaltspunkte und einen klaren Plan für einen erfolgreichen Antrag auf Zulassung für Oral-lyn(TM) und wir werden alles tun um diese Anforderungen möglichst rasch zu erfüllen und den Zulassungsantrag vorbereiten."

Dies erweckt den Eindruck als könne der Antrag relativ zügig erfolgen.

Zur Vogelgrippe:
Es kann natürlich jederzeit eine Meldung kommen, dass die GNBT von der US Regierung Fördermittel erhält, um die Entwicklung eines Impstoffes zu beschleunigen.

Also was jetzt tun?
Jeder sollte dies selbst entscheiden.
Kerzentechnisch wurde am Freitag ein leichtes Kaufsignal erzeugt.
Insgesamt sind die Indikatoren jedoch nicht eindeutig.

http://bigcharts.marketwatch.com/intchart/frames/frames.asp?…

therman

[therman]

Noch ein Hinweis auf eine Aktie, der ich langfristig viel Potential zutraue wie GNBT, und in der ich ebenfalls langfristig investiert bin

Es ist Globetel communications, GTE.
Infos im thread:

Thread: Globetel Corp. GlobeTel Communications Corp. (GTEL)

und Thread: GTE - Globetel Communications Corp - Megachance

therman

[Onkelbaer]

Hi therman,

also wie geschrieben, diese Ungewissheit bzl. der Zulassung in Kanada, in der Investoren zur Zeit von GNBT gelassen werden, ist der Grund fuer die zur Zeit unklare Richtung der Kursentwicklung. Zu beiden Szenarien, die Du erwaehnst, ist zu sagen, dass das in beiden Faellen KRIMINELL waere. Es wuerden entweder potentiell negative Informationen (laengere Dauer hoehere Kosten) nicht publiziert, um den Aktienkurs zu stuetzen und vielleicht ein paar Insidern die Moeglichkeit zu geben noch rechtzeitig auszusteigen. ODER es werden positive Informationen zurueckgehalten, damit Insider noch guenstig einsteigen koennen. Das waere in beiden Faellen Insiderhandel und wird in den USA ziemlich hart, nicht selten sogar mit Knast, bestraft. Also ich gehe einfach mal davon aus, vielleicht ist das auch eine naive Denkweise von mir, dass wir es beim GNBT Management nicht mit kriminellen Kursmanipulatoren zu tun haben. Also sollte es auch noch eine andere Begruendung geben, von der wir hoffentlich bald, dh. natuerlich ERST NACHDEM ich selbst meine volle Position aufgebaut habe , erfahren werden! Soviel dazu!

Jetzt zur Vogelgrippe. Ich verstehe, dass diese zur Zeit in aller Munde ist, weil staendige neue Faelle in neuen Laendern publik werden, aber warum dass im Augenblick irgendeinen Einfluss auf den Aktienwert von GNBT haben soll, weiss ich nun absolut nicht. Vielleicht kann mir das hier jemand erklaeren!? Das Einzige, was man von GNBT zur Zeit weiss, ist, dass sie BEABSICHTIGEN einen Impfstoff dagegen zu entwickeln. Dieser ist aber in seiner Entwicklung wenn ueberhaupt noch in den Kinderschuhen, dh. noch in der vorklinischen Erprobungsphase. Da wird also vielleicht ein erster Wirkstoff an Tieren getestet. Klinische Erprobung Phase I-III dauert, so weit ich weiss, normalerweise 3-5 Jahrem die sehr viel kosten und trotzdem ein grosses Risiko beinhalten, dass nichts daraus wird. Aber selbst wenn Alles gut geht, wird ein solcher Impfstoff im Besten Falle vielleicht 2009 auf den Markt kommen. Warum sollte das daher den Wert der Aktie heute oder morgen bei all den Risiken (positiv) beinflussen?

Nur um das klarzustellen, ich bin absolut kein Basher, auch wenn sich das vielleicht hier im Augenblick so anhoert. Ich bin i.A. sehr positiv gegenueber GNBT eingestellt. Das liegt zur Zeit allerdings fast ausschliesslich an der wirklich greifbaren Oral-lyn Story. Denn das ist was Realistisches und Konkretes, das schon in naechster Zeit noch wesentlich mehr Umsaetze und Gewinne generieren kann, insbesondere dann, wenn man recht einfach, kostenguenstig und schnell Oral-lyn zur kanadischen Marktreife bringen koennte. Alles andere, wie Impfstoff gegen Vogelgrippe oder auch Aids wie man auf der GNBT Homepage nachlesen kann, ist fuer mich zur Zeit absoluter Hokus Pokus.

Greets Onkelbaer

[sebcoe]

was uns weiterbringen würde ist m.E. die beantwortung der frage, ob und inwieweit oral lyn den menschen, die es in ecuador verabreicht bekommen, linderung verschafft.
ist das medikamant wirksam und treten keine nebenwirkungen auf, dann sollte einer zulassung in kanada nichts im wege stehen, denke ich. ich denke in diesem zusammenhang tun sich so einige fragen auf: wieviele menschen bekommen oral lyn verschrieben usw. usf. werde leider erst nach rückkehr einer auslandsreise dayzu kommen, zu googlen bzw. die ir anzuschreiben. also, wenn jemand zeit erübrigen kann...

[sebcoe]

nicht überrascht wäre ich, wenn Generex eine wie auch immer geartete partnerschaft mit einem größeren pharmaunternehmen schließt. seitdem die partnerschaft mit eli lilly zu bruch gegangen ist, ist das unternehmen ja nicht unattraktiver geworden bzw.schlechter aufgestellt.
die tatsache, dass die fda grünes licht zur aufnahme klinischer tests für den entwickelten impfstoff gegen h5n1 gegeben hat, gewährleistet, dass zusätzliche phantasie aufkommt.

[therman]

[posting]20.523.584 von Onkelbaer am 05.03.06 17:38:33[/posting]Hi Onkelbaer,

das sehe ich auch so: die Unsicherheit bewirkt Kursschwäche.

Mit dem Insiderhandel sehe ich das anderst.
Gnbt kann auf jeden fall mit recht behaupten, dass sie nicht genau wissen , wann sie die zulassung beantragen.
Also wäre es eher gefährlich und fahrlässig jetzt ein genaues Datum für die zulassung zu nennen.

Auch andere unternehmen haben in der vergangenheit in dieser beziehung gleich gehandelt wie jetzt GNBT.

Und wenn andere kaufen, z.B. ein zukünftiger partner, wäre sowieso kein insiderhandel.

dies ist eine vorgehensweise, die nicht unüblich ist.

Was die vogelgrippe anbelangt gilt: an der börse wird die zukunft und phantasie gehandelt und nicht die gegenwart, denn sonst müsste GNBT jetzt höchstens bei 1$ stehen, und für viele andere Aktien gilt das ebenso.

therman

[Onkelbaer]

[posting]20.525.299 von therman am 05.03.06 19:59:02[/posting]Natuerlich wird an der Boerse die Zukunft gehandelt, allerdings ist fuer mich zumindest die nahe Zukunft, dh. die Entwicklung von Oral-lyn, das was mich an der Aktie reizt, aber nicht ein Hokus Pokus, der vielleicht irgendwann in 5 Jahren mal sein koennte.

Das sind mir viel zu viele Konjunktive und Eventualitaeten im Spiel. Wenn`s GNBT schaffen sollte einen solchen Impfstoff auf den Markt zu bringen, umso besser, aber damit rechnen tue ich zur Zeit noch nicht. Ich glaube ausserdem, dass es zur Zeit ziemlich fahrlaessig waere, wenn man wegen irgendeiner blumigen Phantasie wegen eines Vogelgrippe Impfstoffes dies Aktie kauft.

Naja, wie dem auch sei, ist ja nur meine Meinung, und wenn einer die Aktie aus anderen Gruenden als Oral-lyn kauft, soll mir das am Ende auch nur recht sein, weil jeder Kauf zur direkt oder indirekt zur Kurssteigerung der Aktie beitraegt.

Greets Onkelbaer

[talla3xlc]

halten wir heute die 2 €??

[therman]

[posting]20.525.617 von Onkelbaer am 05.03.06 20:43:22[/posting]Da stimme ich mit dir überein, ich bin nicht wegen dem vogelgrippeimpfstoff investiert, sondern wegen Oral-lyn.

Die Phantasie wegen der vogelgrippe hilft zusätzlich dem aktienkurs.


therman

[therman]

[posting]20.529.273 von talla3xlc am 06.03.06 09:15:55[/posting]Die kurse in deutschland sind bedeutungslos.

was zählt sind die kurse in USA.

therman

[benmuhs]

...warum fällt das S******teil denn hier ?!
Also manchmal verstehe das wer will !

[Onkelbaer]

[posting]20.530.232 von benmuhs am 06.03.06 10:11:49[/posting]Schnelle einfache Antwort auf Deine Frage. Wie therman schon richtig geschrieben hat, der Kurs wird in USA gemacht, und die deutschen Boersen richten sich bisher noch nach dem Schlusskurs aus USA. 2,32 Dollar = 2.32/1.202 Euro = 1.93 Euro und siehe da, genau bei diesem Eurokurs wird zur Zeit gehandelt.

Greets Onkelbaer

[HoTsTePPa.]

SK: 2,24 $ ~ 1,86 €

[elfederiQo]

-8% bis -10% aktuell in USA (2,07 USD, low bei 2,01)....

[elfederiQo]

scheint sich vorerst bei 2,12 einzupendeln...immerhin
5%

[hri]

news :

Press Release Source: Generex Biotechnology


Generex Biotechnology Announces Positive Preliminary Results in a Long-Term Clinical Trial of Generex Oral-lyn(TM) in Juvenile Patients With Type-1 Diabetes Mellitus (DM)
Wednesday March 8, 8:45 am ET


TORONTO--(MARKET WIRE)--Mar 8, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, announced today positive preliminary results (10 weeks) of a long-term (six month) clinical trial of Generex Oral-lyn, the Company`s proprietary oral insulin spray product, in juvenile patients with Type-1 diabetes mellitus (DM).

[therman]

Diese positiven Zwischenergebnisse beinhalten keine wirklichen Neuigkeiten.
Was hier gesagt wird, ist schon bekannt aus vorherigen Veruschsreihen.
Was fehlt, ist die Aussage, ob diese Studie, wenn sie fertig ist, ausreicht um eine Zulassung zu beantragen.


Der Zeitpunkt dieser Pressemeldung ist von GNBT meiner Meinung nach gewählt worden, um den Kurs zu stützen.

therman

[sebcoe]

verkaufsdruck womöglich gapschluß 1,62?

[Onkelbaer]

So, bin jetzt auch mit einer ersten Position mit an Board, von mir aus darf`s also jetzt wieder gegen die $3 laufen. Fand ich ganz lieb von Euch, dass Ihr so brav auf mich gewartet habt.

Hatte Anfang letzter Woche schon die Befuerchtung, dass der Zug ohne mich abgefahren ist, aber jetzt bin ich einfach nur froh, dass ich damals nicht die Panik gekriegt habe, und wie wild hinterher gesprungen bin!

Auf eine erfolgreiche zukuenftige Entwicklung von GNBT und des Aktienwerts.

Greets Onkelbaer

[hri]

ich bin seit mittwoch wieder dabei zu 1,63, schöner abstauber vorbörslich hoffe das noch einige shorts covern vorm weekend

[tobijack]

hallo
jemand eine ahnung warum es in norden geht

[tippse]

dies ist der grund:

Generex Biotechnology to Present Its Avian Influenza Vaccine Program at DNA Forum in London

TUESDAY, MARCH 14, 2006 8:30 AM
- Market Wire

TORONTO, Mar 14, 2006 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (GNBT) announced today that Dr. Douglas Powell, Ph.D., Director of Immunobiology at Antigen Express, Inc., the Company`s wholly owned immunotherapeutics subsidiary, will present the Antigen Express H5N1 avian influenza vaccine program at the upcoming Third Annual DNA Vaccines Forum to be held in London, UK, March 17 - 18, 2006.

The strategy employed by Antigen Express focusing on the development of its novel H5N1 avian influenza vaccine utilizes small portions of the H5 protein that are modified to enhance antigen-specific stimulation of T-helper cells. Upon infection, such T-helper cell responses enhance the speed and strength of neutralizing antibody production. It is anticipated that the vaccine being developed will both impart some level of protection on its own and enhance the activity of other types of avian influenza vaccines, including DNA vaccines.

The meeting will focus on the latest advances involving DNA vaccine technology as well as clinical experiences and regulatory issues. All vaccines that are currently approved for human use are inactivated or attenuated (weakened) viruses or recombinant protein vaccines. DNA vaccines are a promising new approach with the potential to prevent many infectious diseases such as H5N1 influenza, anthrax and plague. Although a number of DNA vaccines are currently in clinical trials, none have been approved for use in humans. One of the challenges facing the use of DNA vaccines is that the responses generated in humans may be insufficient to prevent infection. To address this issue, scientists have investigated numerous methods to enhance the immunogenicity of DNA vaccines including the use of novel adjuvants and cytokines. For many diseases, including influenza, the generation of neutralizing antibodies produced by B lymphocytes is sufficient to protect against infection. The CD4 T cell response is essential for generating high levels of neutralizing antibodies in addition to eliciting memory T and B cell responses that provide protection against future infections. CD4 T cells recognize MHC class II epitopes presented on the surface of antigen presenting cells. Dr. Douglas Powell and Dr. John Zinckgraf at Antigen Express have demonstrated that immunization of mice with MHC class II epitopes derived from the H5N1 influenza hemagglutinin protein coupled to the proprietary Ii-Key peptide greatly enhances the CD4 T cell responses to a DNA vaccine encoding the H5N1 influenza hemagglutinin protein and may be used as a strategy to increase the immunogenicity of DNA vaccines.

One of the major challenges facing immunization with many of the currently available vaccines is the need for refrigeration, often referred to as maintenance of the cold chain. This is a particularly difficult problem in developing countries with limited medical resources. One of the advantages of a vaccine utilizing peptides and DNA is that both of these components can be lyophilized, stored at ambient temperatures and reconstituted "on-site" with saline. "We have promising data in an animal model suggesting that we will be able to achieve levels of immunity consistent with protection from H5N1," said Dr. Powell. The company has recently completed a pre-IND meeting with the FDA and hopes to enter human clinical trials of its peptide vaccine against H5N1 later this year.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company`s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company`s proprietary RapidMist(TM) device. The Company`s flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


Contact:
Shayne Gilliatt
Generex Biotechnology Corporation
Phone: [phone] and [phone]
Ed Lewis
CEOcast, Inc.
Phone: [phone]


SOURCE: Generex Biotechnology
Copyright 2006 Market Wire, All rights reserved.

[tobijack]

vielen dank

[simsalabam]

[posting]20.614.607 von hri am 10.03.06 14:49:41[/posting]bist noch dabei

[therman]

Hi,

habe heute meine Tradingaktien, die ich nach dem Kaufsignal am 09.03. zu 2,19$ gekauft habe,
heute zu 2,95$ wieder verkauft.

Ich gehe davon aus, dass kurzfristig nicht mehr viel Spielraum nach oben ist.

Habe die Absicht wieder günstiger zurückzukaufen.

Den langfristigen Teil halte ich weiter.


therman

P.S.Habe im moment wenig zeit hier zu posten.

[tippse]

Antwort auf Beitrag Nr.: 20.769.836 von therman am 17.03.06 16:38:11

war auch am überlegen langsam wieder einzusteigen - aber heute wieder über 7% heruntergerauscht. folgende meldung könnte der grund sein (könnte mir gnbt in den nächsten tagen sogar als short-kandidat vorstellen ..)

*******************************************************************

Emisphere Completes Enrollment for Phase II Oral Insulin Clinical Trial

No Safety Concerns Raised to Date on Oral Insulin Product
Company Receives Approval to Expand Study from 120 to 140 Patients

TARRYTOWN, N.Y., April 11 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced it has completed enrollment of the first 120 patients in its Phase II oral insulin clinical trial (the "Trial"), and has received permission from regulatory authorities in India to expand the Trial enrollment from 120 patients to 140 patients. By expanding the Trial, Emisphere will be able to evaluate the performance of all three active arms of the Trial against each other for statistical significance. Without the additional patients, Emisphere would have been limited to evaluating each of the active arms against only the placebo for statistical significance. Based on the current enrollment rate, the Company expects to complete the additional enrollment within the next few weeks.

"Expanding our trial enrollment will give us a more robust data set to compare the three different dosing regimens of oral insulin being tested in this Trial," commented Michael M. Goldberg, M.D., Chairman and Chief Executive Officer of Emisphere Technologies. "We are pleased with the safety and activities observed to date, and are delighted that the DCGI granted us permission to increase enrollment. We expect to complete the Trial, and look forward to un-blinding and reporting the results during the second half of this year."

Emisphere is closely monitoring the blinded data received from the Trial, and as of April 1, fifty nine (59) patients have had their 30-day visit, twenty two (22) patients have had their 60-day visit, and a small number of patients have completed the end of study 90-day visit. The Company is encouraged by the meaningful number of patients showing a greater than one percent drop in their hemoglobin A1c (HbA1c) at 60 days. In addition, these patients are not showing weight gain, which is very commonly seen with insulin treatment. There have been no reported cases of treatment-related serious adverse events or hypoglycemia. Hypoglycemia is also very commonly observed in diabetic patients treated with insulin, and as a result, insulin therapy requires patients to frequently monitor their blood sugar and adjust their insulin therapy accordingly. One of the primary objectives of the Trial is to test the hypothesis that oral insulin can be administered as a fixed dose without the need to frequently monitor the patients' blood.

In November 2005, Emisphere commenced enrollment for the 90-day, multi-center, randomized Trial. The four-arm study will evaluate the safety and efficacy of low and high fixed doses of oral insulin tablets versus placebo in 120 patients with Type 2 Diabetes Mellitus who have inadequate glycemic control with their existing oral metformin monotherapy. The primary efficacy endpoint of the Trial is related to the change in HbA1c, the standard for evaluating glucose control in Type II diabetics. Emisphere also will focus on the safety of oral insulin, specifically incidents of hypoglycemia, as well as the occurrence of insulin antibodies.

http://www.emisphere.com/press_releases.asp

*******************************************************************


es gehen also auch andere auf die dörfer zum tanzen das "gschmäckle" dabei ist die partnerliste von emisphere: novartis, roche, genta ...
sollten sich hier erfolge einstellen hat emisphere natürlich potente partner im boot. mal weiter beobachten.

[Onkelbaer]

Antwort auf Beitrag Nr.: 21.167.084 von tippse am 11.04.06 21:26:57

Also nur ne schnelle Antwort auf Dein Posting und die reingestellte PR.

1.) Es ist klar, dass GNBT kein Monopol auf orales Insulin haben wird.
2.) Oral-Lyn hat einen entscheidenden Vorteil gegenueber den Tabletten, von denen dort in der PR gesprochen wird. Die Aufnahme-Zeit ist vergleichbar schnell, wie die bei einer Injektion. Dh. Diabetiker, die zur Zeit an der Nadel haengen, koennen ganz einfach auf Oral-Lyn umsteigen und ihr Verhalten bzgl. der Zufuhr (dh. Menge und Zeit) beibehalten. Bei Tabletten entsteht immer die Verzoegerung, dadurch, dass die Tablette erst im Magen zersetzt werden muss, um das Insulin freizusetzen.
3.) Waehrend es in der PR heisst, dass hier gerade die Phase II eingeleitet wird, ist GNBT schon halb damit durch und hat ja gerade gestern erst nen sehr vielversprechenden Zwischenbericht veroeffentlicht!
4.) Das mit dem grossen Partner im Boot hat immer auch einen grossen Haken, denn der grosse Partner macht das natuerlich auch nicht aus karitativen Zwecken. Die werden einen grossen Teil vom Kuchen abgekommen wollen und auch kriegen.
5.) Genau aus diesem Grund hat sich GNBT vom grossen Partner Eli Lilly getrennt und ist den Weg ueber die Zulassung in Equador und hoffentlich bald weiteren Laendern in S.A. gegangen. Ueber den Verkauf in Equador soll dann die weiteren klinischen Tests finanziert werden, um eines Tages auch die Zulassung erst in Kanada und dann in den USA zu erhalten. Ist das eines Tages der Fall, gehen die Einkuenfte auch (nahezu) komplett in die eigene Kasse.
6.) Man strebt insgesamt auch nur einen Weltmarktanteil von 2% an und glaubt damit immer noch 1 Mrd. USD Umsatz machen zu koennen.
7.) Hast Du Dir mal die Frage gestellt, warum diese "Emisphere" Produkt seine klinischen Tests in Indien durchfuehrt? Vielleicht wird es da eines Tages ein Problem mit der Anerkennung der Studien durch die US FDA geben, und der US Markt ist immer noch der wichtigste Biotech-Markt!

Soviel dazu fuer den Augenblick!

Greets Onkelbaer

P.S.: Fuer mich ist Deine Begruendung fuer den Kursrutsch damit keine. Verstehen tue ich diesen daher immer noch nicht!